



(51) International Patent Classification:

A01K 67/02 (2006.01) G01N 1/30 (2006.01)
A01N 1/02 (2006.01)

(21) International Application Number:

PCT/US2012/040553

(22) International Filing Date:

1 June 2012 (01.06.2012)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/492,151 1 June 2011 (01.06.2011) US
61/569,143 9 December 2011 (09.12.2011) US
61/570,691 14 December 2011 (14.12.2011) US

(71) Applicant (for all designated States except US): **INGUR-AN, LLC** [US/US]; 22575 State Highway 6 South, Navasota, TX 77868 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **LENZ, Richard** [US/US]; 22575 State Highway 6 South, Navasota, TX

77868 (US). **MORENO, Juan** [US/US]; 22575 State Highway 6 South, Navasota, TX 77868 (US). **VISH-WANATH, Ramakrishnan** [NZ/NZ]; 22575 State Highway 6 South, Navasota, TX 77868 (US).

(74) Agents: **EWELL, Cindee** et al.; Inguran, LLC, 22575 State Highway 6 South, Navasota, TX 77868 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,

[Continued on next page]

(54) Title: COMPOSITIONS AND METHODS FOR IMPROVING THE QUALITY OF PROCESSED SPERM

(57) Abstract: The present invention relates to compositions and methods for the handling of processed sperm including samples that are freshly collected, those transported as fresh samples, samples that are frozen and thawed, those sorted into one or more subpopulations, and those that are otherwise processed or handled that impose trauma on the cell. Trauma can reduce the motility, fertility, viability and overall integrity of the sperm and reduce the ability to fertilize, produce an embryo and a healthy offspring. The present invention relates to novel compounds that can be added to the sperm cell sample to reduce the traumatic effects of physical stress during mild as well as extensive sperm cell processing, methods of using the compounds in standard sperm processing procedures, the end products made from these methods including sperm and embryos, as well as methods of using those end products in assisted reproductive biology techniques in animals.




FIG. 1





EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,
LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK,
SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG).

— of inventorship (Rule 4.17(iv))

Published:

— with international search report (Art. 21(3))

— before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted
a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of
the earlier application (Rule 4.17(iii))

COMPOSITIONS AND METHODS FOR IMPROVING THE QUALITY OF PROCESSED SPERM

This application claims priority to U.S. Provisional Applications 61/492,151 filed June 1, 2011, entitled "Method of sorting sperm cells into one or more subpopulations and methods of treating sperm cells to improve motility;" 61/569,143 filed December 9, 2011, entitled "Methods of handling processed sperm cells to improve their quality;" and 61/570,691 filed December 14, 2011, entitled "Methods of handling processed sperm cells to improve their quality," the contents of which are all incorporated by reference in their entireties.

The present invention generally relates to compositions and methods for the handling of processed sperm populations, including those freshly collected as well as those sorted into one or more subpopulations, and for treating processed and/or handled semen samples and solutions that contain sperm cells to increase the overall quality of the processed sperm, including their viability, motility, fertility, DNA integrity, and in vitro longevity. The present invention also relates to compositions comprising sperm cells and at least one compound that may be an antioxidant, vitamin or other organic stress reducer, the methods of using these compounds to reduce trauma and stress on processed sperm, the resulting sperm and embryo end products, and the methods of use of these products in assisted reproductive technologies (ART) to increase the quality, quantity and viability of embryos, and improved rates of births in animals.

BACKGROUND

Assisted reproductive technology (ART) includes such techniques as in vitro fertilization (IVF), artificial insemination (AI), intracytoplasmic sperm injection (ICSI) (other techniques using enucleated cells) and multiple ovulation and embryo transfer (MOET) (as well as other embryo transfer techniques), is used across the animal kingdom, including humans and other animals. ART methods are usually expensive, time consuming and marginally successful given the inherent fragility of gametes and embryos when outside of their natural environments. Furthermore, the use of ART within the animal breeding industry in a commercially feasible manner is additionally challenging due to the limited availability of genetically desirable gametes and zygotes. One way to lower the cost of ART and to improve its commercial feasibility is to increase the efficiency of the involved processes by improving the viability and overall quality of gametes and zygotes. Although there is has been a growing interest in this field over the course

of the last decade or so, there still remains a strong need to increase the overall quality of gametes and zygotes for use in ART, especially when breeding focuses on pre-natal gender selection, including improving their viability (in the case of gametes and zygotes), their motility and fertility (in the case of sperm cells), as well as other longevity characteristics.

For example, in conventional AI, one problem limiting its commercial application in certain species is the need to use extremely high number of sperm cells per AI dose to ensure successful fertilization. Similarly, in IVF, the percentage of zygotes that develop into embryos remains frustratingly low; this high rate of loss significantly increases the cost of embryos and related services to end-users. There also remains the need for more efficient and lower cost procedures for improving post-embryo handling through cryopreservation as well as non-frozen transport. Cryopreservation of embryos is limited by the success rate of embryo production as well as blastocyst growth in vitro. Currently, only a marginal percentage of IVF embryos are suitable for cryopreservation which adds to the ongoing high cost of ART procedures.

Especially when processing gametes such as flushed oocytes or sperm cells, both conventional and sex-sorted, before their use in ART adds a tremendous amount of stress on the gamete cell and negatively impacts their cellular integrity and membrane structure which in turn is reflected in decreased viability, motility and fertility. An example of processing gametes prior to their use in ART is the sorting of sperm cells based on sex (known as “gender enrichment” or “sex-sorting”), which is a highly desired procedure to minimize wasted births of the wrong sex for selective breeding in the livestock industry but is often cost prohibitive and can be risky to those with smaller breeding herds.

The popular flow cytometry based sex-sorting process severely stresses and damages the cells and produces a low percentage of useful sperm, which although capable of fertilizing matured oocytes, have reduced viability, motility and fertility after the sex-sorting process. Typically, sex-sorting involves many harsh steps including but not limited to: the initial collection and handling of sperm ejaculate which naturally starts to deteriorate rapidly upon collection; the staining of sperm cells which involves binding of an excitable dye to the DNA or a harmful membrane selection procedure; the physical sorting of the sperm cells using high energy fluorescence that physically energizes the dye that is bound to the DNA, forced orientation through a narrow orifice, and application of an electrical charge to the cell; the physical collection of the cells into a container which often shocks the fragile cell upon contact;

the osmotic stresses associated with dilution of the sperm droplet in collection media; and the storage of the sorted sperm usually by freezing which is well known to raise havoc with the cell's membrane systems. Each step places the processed sperm under abnormal stress which diminishes the overall motility, viability and/or fertility of the sperm. The result can lead to less efficient samples for use in ART, such as IVF and AI, and other types of subsequent or further processing.

Even non-sorted processed sperm exhibits significant losses in fertility, viability and motility when being collected, handled and transported without freezing, and noticeably experiences significant stress when mixed with cryoprotectant and is frozen and thawed. Many in the field have tried to improve methods for the use on unsorted, conventional semen to minimize loss in the handling processes associated with in vitro handling, preservation and use of semen samples.

Regardless of the processing, sperm lose their potential to fertilize when exposed to: elevated temperatures, abnormal buffers, stains, altered pH systems, physical pressurized orientation as when forced through a nozzle or when oscillated to form drops in a flow cytometer, radiation used to illuminate the DNA binding dye, physical stressors associated with separation and collection techniques, cryoprotectants, freezing, thawing and micromanipulation by the handler.

The large class of compounds referred to as antioxidants have been associated with providing beneficial effects to all sorts of cells, in vivo and in vitro, but these effects are as varied as the nature of the antioxidant itself. An antioxidant is simply one of a large variety of molecules that either inhibit the oxidation of another molecule, becomes oxidized itself in place of the target substrate, or binds harmful free radical intermediates and interrupts oxidative chain reactions within a cell. Most have dual roles; some are enzymes, others are non-enzymatic; some others are vitamins and others are cofactors. Such diversity lauds the diversity of antioxidants, but because of their known ability to minimize cell damage, they are frequently lumped together as a single class of compounds having only a single function, to bind free radicals.

Various antioxidants have shown promise in promoting cell integrity with some reports showing positive effects on sperm motility and membrane integrity during cryopreservation, but some tests have been shown to have minimal or even harmful effects on processed sperm.

Similarly, vitamins are again a rather diverse group of molecules having very different biological properties. Vitamins are any of a large group of organic compounds required in very small amounts as vital nutrients for an organism that cannot synthesize it. They can be antioxidants, enzymes, hormones or non-enzymes; they can be regulators of cell growth, cell differentiation or moderators of mineral metabolism.

To date, no studies have sufficiently addressed the use of antioxidants, vitamins or other supplements in the routine handling of fragile gametes during in vitro processing, especially during the harsh processing associated with the sex-sorting of sperm, whereby the end result is a reproducible improvement on the viability, motility and fertility of extensively processed sperm cells and embryos. There remains a continuing need to improve current methods of ART to reduce the cost and to make the procedures more dependable and commercially feasible to those on a tight budget, especially those smaller breeders who view sex-selection breeding as a high risk and expensive option.

SUMMARY OF THE INVENTION

A broad object of the present invention is to provide improvements in the motility, viability, fertility and overall integrity of processed sperm cells. Accordingly, one embodiment of the present invention comprises a method of treating sperm cells by adding at least one "organic stress reducing" agent (OSR) which may comprise an antioxidant, a vitamin or other organic molecule involved directly or indirectly in modulating physiological stresses in the cell. The OSR would be added in the concentration range of 0.01 mg/ml to 5 mg/ml to a sperm cell sample to form a sperm cell composition. In certain embodiments, one or more OSRs, each in the concentration range of 0.01 mg/ml to 5 mg/ml, can be added to the sperm cell sample prior to cryopreservation (including, for example, freezing and vitrification), after the sperm cell sample has been thawed, or at both times. In other embodiments, the OSR can be added at one or more of the various stages during the sperm cell processing procedure. The term "sperm cell sample" may comprise a processed semen sample or an unsorted, conventional semen sample.

Another specific embodiment of the invention comprises the sperm cell composition comprising a sperm cell sample and at least one OSR in the concentration range of 0.01 mg/ml to 5 mg/ml. Another embodiment encompasses a "sperm cell composition" comprising a sperm cell sample, at least one OSR in the concentration range of 0.01 mg/ml to 5 mg/ml and a cryoprotectant. Most cryoprotectants can be used with the invention, including but not limited to

egg yolk, propylene glycol, dimethyl sulfoxide, sucrose, ethylene glycol and glycerol, or a combination thereof. One embodiment encompasses a fresh, an unfrozen, a frozen, a vitrified, or a thawed sperm cell composition comprising a sperm cell sample and at least one OSR in the concentration range of 0.01 mg/ml to 5 mg/ml. Another embodiment encompasses a fresh, an unfrozen, a frozen, a vitrified, or a thawed sperm cell composition comprising a sperm cell sample, at least one antioxidant and/or one vitamin in the concentration range of 0.01 mg/ml to 5 mg/ml, and a stain.

Another broad object of the present invention is to improve the motility, viability (including longevity and ability to survive environmental stress) and/or fertility of sperm cells, each contributing to the sperm cell's overall integrity, to improve the success of using ART, including techniques such as IVF, AI, ICSI (as well as other techniques using enucleated cells), and MOET (as well as other embryo transfer techniques).

Such ART techniques involve different levels of gamete cell processing which in the case of sperm can entail, by example only and is not limited to one or more of the following: artificially collecting a semen sample from the male animal which may involve natural, electronic or other types of sexual stimulation; holding; transporting; buffering with different pHs; chilling; warming; staining; diluting; concentrating; energetically exciting as with a laser; electronic charging; deflecting; ablating to kill unwanted cells usually with targeted lasers; sorting; collecting; shaking; oscillating; magnetically separating; oxygenating as associated with microchip sorting procedures; labeling; precipitating; centrifuging; resuspending; mixing; dialyzing; cryostabilizing; freezing; vitrification; thawing; culturing; inseminating; microinjecting; microfluidic processing; microchip processing; jet and air processing; flow cytometry processing; and similar handling techniques. Whereas a single processing step may exert only minimal stress on a sperm cell, others or a combination may add significant stress, often killing the cell. An extreme example is the sex-sorting process used to separate X- from Y-chromosome bearing cells; the sorting process combines a large number of independent highly stressful steps that severely compromise the overall integrity of the sorted sperm cell population.

Accordingly, one embodiment of the present invention resides broadly in the use of a sperm cell composition, comprising a sperm cell sample and at least one antioxidant and/or at least one vitamin in the concentration range of 0.01 mg/ml to 5 mg/ml, in ART. One specific embodiment of the invention comprises a method of increasing the percentage of zygotes that

develop into embryos in a given sample in a given amount of time, as well as increasing the percentage of embryos that are suitable for cryopreservation (i.e., the percentage of embryos that are blastocysts, expanded and hatching blastocysts, or hatched blastocysts), by mixing an egg with a sperm cell sample that has been treated with at least one OSR in the concentration range of 0.01 mg/ml to 5 mg/ml. A further embodiment of the invention resides in a method of making an embryo comprising mixing at least one egg with a sample of sperm cells treated with at least one OSR in the concentration range of 0.01 mg/ml to 5 mg/ml. The embryos produced by this method constitute a further embodiment of the invention. Another embodiment includes a method for inseminating an organism through an AI technique using a sperm cell sample treated with at least one OSR in the concentration of 0.01 mg/ml to 5 mg/ml. Another embodiment includes a method of transferring an embryo into a receptive female (ET) where said embryo is made using a sperm cell sample treated with at least one OSR in the concentration of 0.01 mg/ml to 5 mg/ml. The progeny of the organism that results from the aforementioned AI method also constitutes an embodiment of the invention.

Most embodiments of the invention utilize concentrations of OSRs selected from the following ranges: 0.01 to 5.0 mg/ml; 0.01 to 0.25 mg/ml; 0.01 to 0.5 mg/ml; 0.01 to 1 mg/ml; 0.01 to 2.5 mg/ml; 0.01 to 5 mg/ml; 0.05 to 0.1 mg/ml; 0.05 to 1.0 mg/ml; 0.05 to 2.5 mg/ml; 0.1 to 0.25 mg/ml; 0.1 to 0.5 mg/ml; 0.1 to 1 mg/ml; 0.1 to 2.5 mg/ml; 0.1 to 5 mg/ml; 0.15 to 0.45 mg/ml; 0.15 to 0.5 mg/ml; 0.25 to 0.35 mg/ml; 0.25 to 0.5 mg/ml; 0.25 to 1 mg/ml; 0.25 to 2.5 mg/ml; 0.25 to 5 mg/ml; 0.35 to 0.5 mg/ml; 0.35 to 1 mg/ml; 0.35 to 2.5 mg/ml; 0.35 to 5 mg/ml; 0.5 to 1 mg/ml; 0.5 to 2.5 mg/ml; 0.5 to 5 mg/ml; 1 to 2.5 mg/ml; 1 to 5 mg/ml; about 0.05 mg/ml; about 0.1 mg/ml; about 0.15 mg/ml; about 0.25 mg/ml; about 0.35 mg/ml; about 0.45 mg/ml; and about 0.5 mg/ml.

In some embodiments of the invention the sperm cell composition can be used immediately or processed within the first few minutes after addition of the OSR for whatever processing step is needed, whereby the holding period would be in the range 2 sec to 3 min. In other embodiments, the sperm cell composition is held after the addition of the OSR(s) to allow the OSR(s) to incorporate into the cells and effectuate protective effects on the cell population. Such holding periods can be short, as in the range of a 3-15 minutes, moderate as in the range of 15 min to 1 hr; and longer processing periods ranging up to about 8 hrs or overnight for extensive processing such as with sex-sorting techniques. Transportation hold periods associated

with transporting unfrozen sperm cell compositions can be much longer, extending up to a few days, which may for example occur if the sample is collected, treated with the addition of one or more OSRs, transported or shipped to another location possibly by air, and further processed at the second location as for sex-sorting at a designated facility. In other instances, the sperm cell composition might need to be held for a few days while a recipient female is hormonally prepped for artificial insemination, as might occur if a sample is mistakenly thawed and cannot be refrozen. The addition of OSRs could theoretically prolong these extended hold periods over what is currently accepted in the art, and could provide sufficient protection to the sperm in the sperm cell composition so that they could remain viable and fertile for up to a week or more.

In some embodiments of the invention, the OSR is added several times during a complex processing procedure to minimize cell stress throughout the procedure. In other embodiments, the OSR is added only at one or more particular steps which are notably harsh on the cells to help minimize stress and fatigue on the sperm cells. By way of example, the staining process during sex sorting is often performed at non-physiological pH and at elevated temperatures, both known to be harsh on the cells. Similarly, cryopreservation is also extremely harsh on the cells and disrupts cell membranes, both internal and external. Following an intensive multi-step sorting procedure, sex-sorted sperm cells which are already compromised are even more susceptible to cryogenic and freeze processing.

Various OSRs can be used in the context of the current invention, including but not limited to: catalase, superoxide dismutase (SOD), SOD mimics, glutathione, glutathione reductase, glutathione peroxidase, pyruvate, mercaptoethanol, butylated hydroxytoluene (BHT), lipoic acid, flavins, quinines, vitamin K (and related vitamers), vitamin B12 (and related vitamers), with 'vitamers' defined as compounds having the same vitamin activity (such as cobalamin, cyanocobalamin, methylcobalamin, adenosylcobalamin, hydroxocobalamin, and pseudo-B12), vitamin E (including its vitamers, tocopherols (α , β , γ), tocotrienols, and α -tocopheryl), alpha-ketoglutarate (also known as α -KG, AKG or oxo-glutarate) and various biological forms of AKG (such as arginine, aspartate, lysine, and similar derivatives), other compounds that regulate nitric oxide in the cell including malondialdehyde (MDA) and asymmetric dimethylarginine (ADMA) and biologically active derivatives thereof.

A further embodiment of the invention comprises a method of sorting a sperm cell sample to form one or more subpopulations comprising the steps of providing a sperm cell sample, sorting the sperm cell sample to form one or more subpopulations and adding at least one OSR to the sperm cell sample during one or more of the aforementioned sorting steps, the concentration of the OSR being in the range of 0.01 mg/ml to 5 mg/ml.

An additional embodiment of the invention encompasses media used in processing sperm cells that comprise at least one OSR at the appropriate stock concentration to be present at a final processing concentration in the range of 0.01 mg/ml to 5 mg/ml in the sperm cell composition at the time of processing. A stress reducing media can be used for different processes including but not limited to sperm collection, artificial insemination, sperm sorting, in vitro fertilization, embryo culture, as well as sperm and embryo freezing. Media used in the sorting of sperm cells typically comprise one or more buffers and/or extenders (i.e., substances that preserve the viability and/or fertility of sperm cells).

Any buffer or buffer solution used in the processing of sperm can be used in the aforementioned media, including but not limited to phosphates, citrates, acetates, lactates, and combinations thereof, or a solution containing a salt, a carbohydrate, or a combination thereof can be employed in some of the embodiments of the invention, such as, but not limited to: Tris, TES, HEPES, TALP, TCA, PBS, citrate, milk and derivatives thereof, as discussed in detail in U.S. Patent 7,208,265 the contents of which is hereby incorporated by reference in its entirety.

Any extender used in the processing of sperm can be used in the aforementioned media, including but not limited to energy sources, protein sources and antibiotics and may include one or more of the following: mono- and disaccharides, such as fructose, glucose, mannose, sucrose, and lactose; protein sources, such as egg yolk, milk, BSA and derivatives thereof; and any one of the commonly known antimicrobial or antibiotic agents, such as gentamicin, lincomycin, spectinomycin, their derivatives, or any combination thereof.

As used herein, the term "extender" may also include certain organic substances such as disaccharides, trisaccharides, and any combination thereof, egg yolk, milk, albumin, lecithin, cholesterol, their derivatives and any combination thereof. An extender may also include a detergent that may be an alkyl ionic detergent, such as sodium dodecyl sulfate (SDS).

A further embodiment of the present invention provides a method of improving the motility, viability and/or fertility of a sperm cell sample that has already undergone a sorting

process, including but not limited to sex sorting, comprising the step of adding at least one OSR in the concentration range of 0.01 mg/ml to 5 mg/ml to a sorted sperm cell sample to form a sperm cell composition.

Accordingly, the present invention resides broadly in the use of a sperm cell composition, that in some embodiments comprise a sorted sperm cell sample and at least one OSR in the range of 0.01 mg/ml to 5 mg/ml, for use in ART. A further embodiment encompasses a sperm cell composition comprising sorted sperm cells, at least one OSR in the concentration range of 0.01 mg/ml to 5 mg/ml and a catch media (i.e., media found in the vessel that receives, or catches, the sorted sperm at the end of the sorting process). Another embodiment encompasses a sperm cell composition comprising a processed or sorted sperm cell sample, an OSR in the concentration range of 0.01 mg/ml to 5 mg/ml, and a cryoprotectant. An additional embodiment of the invention encompasses a frozen or vitrified sperm cell composition comprising a processed or sorted sperm cell sample, and at least one OSR in the concentration range of 0.01 mg/ml to 5 mg/ml.

Another broad object of the present invention is to improve the motility, viability (including longevity and ability to survive environmental stress) and fertility of processed and/or sorted sperm cells for use in ART such as IVF, AI, ICSI (as well as other techniques using enucleated cells), and MOET (as well as other embryo transfer techniques).

Accordingly, some of the embodiments of the present invention incorporate the use of sex sorted sperm cells that have had an OSR in the concentration range of 0.01 mg/ml to 5 mg/ml added to them in ART.

Accordingly, other embodiments of the present invention incorporate the use of a sperm cell composition, a sorted sperm cell sample, and at least one OSR in the concentration range of 0.01 mg/ml to 5 mg/ml, in ART.

One specific embodiment of the invention comprises a method of increasing the percentage of zygotes that develop into embryos in a given sample in a given amount of time, as well as increasing the percentage of embryos that are suitable for cryopreservation (i.e., the percentage of embryos that are blastocysts, expanded and hatching blastocysts, and hatched blastocysts), by mixing an egg with a sorted sperm cell sample that has been treated with at least one OSR in the concentration range of 0.01 mg/ml to 5 mg/ml.

A further embodiment of the invention resides in a method of making an embryo comprising mixing at least one egg with at least one sperm cell treated with at least one OSR in the concentration range of 0.01 mg/ml to 5 mg/ml. The embryos produced by this method constitute a further embodiment of the invention.

Other embodiments of the invention also include, a method for inseminating an organism through an AI technique using a processed or sorted sperm cell sample treated with at least one OSR in the concentration of 0.01 mg/ml to 5 mg/ml. The progeny of the organism that results from the aforementioned AI method also constitutes an embodiment of the invention. Furthermore, one embodiment of the invention encompasses a method for recovering embryos that are produced from the aforementioned AI method.

Embodiments of the invention can include sperm cells, or spermatozoa, collected from numerous species of male mammals, and the invention should be understood not to be limited to the species of male mammals described by the specific examples within this application. Rather the specific examples within this application are intended to be illustrative of the varied and numerous species of male mammals from which semen can be collected and utilized in certain embodiments of the invention. Embodiments of the invention, for example, may include the sperm cells of humans as well as animals having commercial value for meat or dairy production such as swine, ovine, bovine, equine, deer, elk, buffalo, or the like (naturally the mammals used for meat or dairy production may vary from culture to culture). It may also include the sperm cells of various domesticated mammalian species encompassed by canines and felines, as well as sperm cells of primates, including but not limited to chimpanzees, gorillas, or humans and the spermatozoa from whales, dolphins and other marine mammals. It may also include frozen-thawed sperm cells from all the various mammals above-described and further, including but not limited to, the sperm cells of deceased donors, from rare or exotic mammals, zoological specimens, or endangered species.

BRIEF DESCRIPTION OF THE DRAWINGS

In order that the invention may be more clearly understood, preferred embodiments of the present invention will now be described by way of example only with reference to the accompanying sheets of drawings wherein:

Figure 1 is a schematic representation of part of a flow cytometer illustrating a method of sorting a sperm cell sample into one or more subpopulations according to some embodiments of the present invention.

Figure 2 illustrates a graphical representation of the motility and progressive motility found in Table 1.

Figure 3 is a graphical representation of the percent blastocysts and percent hatching found in Table 4.

Figure 4 is a graphical representation of the percent blastocysts and percent hatching found in Table 5.

Figure 5 is a graphical representation of the percent motile sperm found in Table 1.

Figure 6 is a graphical representation of the percent progressively motile sperm found in Table 1.

DETAILED DESCRIPTION OF THE INVENTION

In one aspect of the present invention, Figure 1 illustrates in schematic form part of a flow cytometer used in a method to sort a sperm cell sample to form one or more subpopulations, the flow cytometer being generally referenced 10. In this particular embodiment sex sorting is taking place so the subpopulations are X-chromosome bearing sperm cells and Y-chromosome bearing sperm cells. Figure 1 represents a single technique for sorting semen, but any known technique for sorting cells known in the art can be used with certain embodiments of the invention. Additional details of the basic sperm sorting apparatus and methodology are described in U.S. Patents 5,135,759 and 7,371,517, the contents of which are hereby incorporated by reference in their entireties.

Once a sperm cell sample has been collected it can be extended as soon after collection with an extender that includes one or more antioxidants or vitamins. The sample is then typically held at a temperature of about 5°C for between about 12 hours to about 18 hours while it is being shipped from the collection point to the flow cytometer 10 for the sorting process. This holding temperature can be in the range of between 4°C and 39°C and is commonly in the range of 4°C and 16°C.

Upon arrival at the flow cytometer, the sample is stained with a DNA selective dye and a quenching dye to form a stained sperm cell sample and subsequently placed into a sperm cell source 11 of the flow cytometer 10. The flow cytometer 10 can be programmed by an operator

to generate two charged droplet streams, one containing X-chromosome bearing sperm cells, charged positively, 12, one containing Y-chromosome bearing sperm cells, charged negatively 13 while an uncharged undeflected stream of dead cells 14 simply goes to waste.

An operator may also choose to program the flow cytometer in such a manner, that both the X- and Y-chromosome bearing sperm are collected using a “high purity sort” (in other words only live X- and Y-chromosome bearing sperm are collected) or to program the flow cytometer to collect both the X- and Y-chromosome bearing sperm using an “enriched sort” (in other words it will collect droplets containing live that were not previously sorted and excluding all initial dead again by the use of Boolean Gate logic available with the computer that controls the flow cytometer). The Boolean Gate logic can also be used to collect only one of either the X- or Y-chromosome bearing sperm.

Initially, a stream of sperm cells under pressure, is deposited into the nozzle 15 from the sperm cell source 11 in a manner such that they are able to be coaxially surrounded by a sheath fluid supplied to the nozzle 15 under pressure from a sheath fluid source 16. An oscillator 17 which may be present can be very precisely controlled via an oscillator control mechanism 18, creating pressure waves within the nozzle 15 which are transmitted to the coaxially surrounded sperm cell stream as it leaves the nozzle orifice 19. As a result, the exiting coaxially surrounded sperm cell stream 20 could eventually and regularly form droplets 21.

The charging of the respective droplet streams is made possible by the cell sensing system 22 which includes a laser 23 which illuminates the nozzle exiting stream 20, and the light emission of the fluorescing stream is detected by a sensor 24. The information received by the sensor 24 is fed to a sorter discrimination system 25 which very rapidly makes the decision as to whether to charge a forming droplet and if so which charge to provide the forming drop and then charges the droplet 21 accordingly.

A characteristic of X-chromosome bearing sperm is that they tend to absorb more fluorochrome dye than Y-chromosome bearing sperm and as such, the amount of light emitted by the laser excited absorbed dye in the X- chromosome bearing sperm differs from that of the Y-chromosome bearing sperm and this difference in characteristic tells the sorter discrimination system 25 which charge to apply to droplets containing only X- or only Y- chromosome bearing sperm cells. Dead cells (or those about to die) have absorbed the quenching dye and the sorter discrimination system 25 does not charge droplets containing such cells.

The charged or uncharged droplet streams then pass between a pair of electrostatically charged plates 26, which cause them to be deflected either one way or the other or not at all depending on their charge into respective collection vessels 28 and 29 to form respectively a gender enriched population of X-chromosome bearing and a gender enriched Y-chromosome bearing sperm cells having a DNA selective dye associated with their DNA. The uncharged non-deflected stream containing a sub-population of dead cells (or those that are about to die) go to the waste container 30.

The collected sex sorted sperm cells may then be frozen and stored or frozen and sent on for further processing (or simply used for further processing immediately), further processing meaning for example, the purposes of research or for use in ART such as IVF, AI, ICSI (as well as other techniques using enucleated cells), and MOET (as well as other embryo transfer techniques).

In alternative embodiments not illustrated, the catch media contained in the otherwise empty collection vessels may also contain OSR in the concentration range of 0.01mg/ml to 5mg/ml. The OSR may be added during this stage of the sorting process (be it sex sorting or other form of sorting) and/or in addition to another method step in the sorting (be it sex sorting or other form of sorting) process.

Furthermore, in the alternative embodiments, the OSR administered in the concentration range of 0.01 mg/ml to 5 mg/ml to the sperm cell sample or composition can be added to the DNA selective dye and/or the quenching dye solutions. Some embodiments include use of one or more OSRs as pre-mixed components of the prepared buffers, extenders, stains, catch fluids, and/or cryo-extenders used in the sex sorting procedure. Accordingly, the OSR may be added to the sperm cell sample at one or more steps during sex-sorting, including when the sperm cell sample is being first handled following collection, and/or stained with a DNA selective dye and/or the quenching dye, and/or at the time of collection from the flow cytometer, and/or later when preparing the sample for cryopreservation by adding the OSR or OSR cocktail to the cryo-extender.

Likewise, some sorting embodiments include sorting of frozen-thawed conventional semen whereby the OSR can be added to the thawed semen sample shortly after thawing and then reverse sorted to produce sex-sorted sperm cell subpopulations which include the addition of an OSR at one or more steps during the extended processing procedure of gender selection.

In some cases, when the sorting of sperm cells is not going to involve sex sorting, a quenching dye without the need for a DNA staining dye may be required, in which case the OSR will only be present in the quenching dye to form the stained sample. In this way, depending on the embodiment chosen, the OSR may again only be added during this stage of the sorting process (be it sex sorting or other form of sorting) or in addition to at least one other method step in the sorting (be it sex sorting or other form of sorting) process.

Again, in the alternative embodiments, the collected sex sorted sperm cells (or in alternative embodiments the sorted, i.e. non-sex sorted sperm cell samples) once frozen will, prior to such further processing, require to be thawed. Either before freezing or upon thawing, the antioxidant, again in the concentration range of 0.01mg/ml to 5mg/ml, may be added to the sample before freezing and/or to the thawed sample. In this way, depending on the embodiment chosen, the OSR may again only be added during this stage of the sorting process (be it sex sorting or other form of sorting) or in addition to at least one other method step in the sorting (be it sex sorting or other form of sorting) process.

In yet further alternative embodiments the time period allowed to elapse after the addition of the OSR, can vary and may be in the range of about 5 seconds to about 72 hours (excluding freezing time and time spent in the freezer or in the cryopreserved state), the lower end of the scale providing for almost immediate sorting of the sperm sample while the upper end of the scale would cover the typical maximum time frame associated with moving a sperm sample from its collection point to its sorting point. This is usually a flight and/or road travel time. More particularly, the time periods may be about 5 seconds to about 3 hours; about 3 hours to about 6 hours; about 6 hours to about 12 hours; about 12 hours to about 18 hours; about 18 hours to about 24 hours; about 24 hours to about 36 hours; about 36 hours to about 48 hours; about 48 hours to about 60 hours; and about 60 hours to about 72 hours; and .

Another alternative embodiment may include the use of an extender within a pH range of 5.5 to 7.8, and frequently at about 6.5; about 6.6; about 6.7; about 6.8; about 6.9; about 7.0; about 7.1; about 7.2; about 7.3; about 7.4; or about 7.5.

As described in the illustrated embodiment, different steps of the method are carried out at different temperatures. In alternative embodiments, at least one of the method steps is carried out within a temperature range selected from the group consisting of about 5°C to about 15°C; about 15°C to about 20°C; about 20°C to about 25°C; about 25°C to about 30°C; about 30°C to

about 35°C; about 35°C to about 40°C and about 40°C to about 45°C. This allows for different steps in the sorting method to be performed within different temperature ranges.

In another aspect of the present invention there is provided a method of treating the motility of sperm cells in a sperm cell sample. In this embodiment, the sperm cell sample, which may be a gender enriched population of X-chromosome bearing or Y-chromosome bearing sperm cells having a DNA selective or DNA binding dye associated with their DNA, a sample sorted into one or more subpopulations or a conventional non-sorted sample, the method of treating the motility of the sperm cells in the sperm cell sample comprises the step of adding an OSR in the concentration range of 0.01 mg/ml to 5mg/ml to the sperm cell sample to form a sperm cell composition (and in this embodiment at a concentration of 0.5 mg/ml). The OSR which is added forms part of an extender which is in a pH range of 6.5 to 7.5 and in particular embodiments, the pH is selected from the group consisting of about 6.5; about 6.6; about 6.7; about 6.8; about 6.9; about 7.0; about 7.1; about 7.2; about 7.3; about 7.4; and about 7.5.

After the addition of the antioxidant, a time period being in the range of about 5 seconds to about 72 hours is allowed to elapse before the sample undergoes further processing in the form of for example, research or for use in assisted reproductive technologies such as IVF, AI, ICSI (as well as other techniques using enucleated cells), and MOET (as well as other embryo transfer techniques). The time period which is allowed to elapse may be selected from the range consisting of: about 5 seconds to about 3 hours; about 3 hours to about 6 hours; about 6 hours to about 12 hours; about 12 hours to about 18 hours; about 18 hours to about 24 hours; about 24 hours to about 36 hours; about 36 hours to about 48 hours; about 48 hours to about 60 hours; and about 60 hours to about 72 hours. The techniques for fertilizing an egg involve the added step of mixing at least one egg with the sperm cell sample. Any conventional technique such as those listed above can be used with the invention, including any conventional IVF or AI technique. Typical IVF techniques are disclosed in WO/0243486, for example, which is incorporated by reference herein in its entirety. Typical AI techniques are disclosed in U.S. Patent No. 6,149,867, for example, which is incorporated by reference herein in its entirety.

In alternative embodiments, the sperm cell sample may have been a frozen sample that has been allowed to thaw. The method may further comprise the step of staining the sperm cell sample or the sperm cell composition with a DNA selective dye if the sample is not a sex sorted sample.

The method may also comprise the step of freezing the sperm cell composition to form a frozen sperm cell composition that may be allowed to thaw. At least one of the method steps in this second aspect of the present invention is carried out within a temperature range selected from the group consisting of about 0°C to about 5°C; about 5°C to about 15°C; about 15°C to about 20°C; about 20°C to about 25°C; about 25°C to about 30°C; about 30°C to about 35°C; about 35°C to about 40°C and about 40°C to about 45°C. Thus, each method step may be carried out at a different or similar temperature range.

SUGGESTED METHODS

By way of example, the following oocyte maturation procedure, IVF procedure, in vitro culture procedure and co-culture procedure may be used with the invention. One skilled in the art will know that variations on these methods exist and that these methods should not be construed to limit the functionality of the current invention. These methods are illustrative only.

1. Oocyte Collection. Collect slaughterhouse oocytes, wash 1X with about 3mL Hepes washing media and with 1X with TCM-199 (Invitrogen, Carlsbad, CA) + 10% Fetal Bovine Serum (FBS). Culture in maturation media for 22 hrs in a CO₂ incubator at 38.5°C. In one embodiment, the maturation media contains TCM-199, FBS, pyruvate, chorionic gonadotropin (e.g., Chorulon (Intervet, Summit NJ)), follicle stimulating hormone (FSH) (e.g., Folltropin (Bioniche, Belleville, Canada)), estradiol, and at least one antibiotic. In a further embodiment, Amikacin (Sigma-Aldrich, St. Louis, MO) can be used as the antibiotic. In another embodiment, the maturation media may also comprise luteinizing hormone.

In one embodiment, the maturation media may comprise 5-20 ml of TCM-199 Earl's; 0.5-2ml of FBS (Thermo Fisher Scientific, Waltham, MA); 10-30 µl of pyruvate (prepared by adding 0.05-0.20 g of sodium pyruvate (Sigma-Aldrich, St. Louis, MO) to 5-20 ml of saline solution); 50-200 µl of chorionic gonadotropin (prepared by adding 5-20 UI of Chorulon (Intervet, Summit NJ) to 5-20 ml of TCM-199 Earl's); 5-20 µl of FSH (prepared by adding 0.001-0.01 g of Folltropin (Bioniche, Belleville, Canada) to 5-20 ml of TCM-199 Earl's); 5-20 µl of estradiol (prepared by adding 0.001-0.05 g of estradiol (Sigma-Aldrich, St. Louis, MO) to 5-20 ml of Etanol (Sigma-Aldrich, St. Louis, MO)); and 10-30 µl Amikacin (prepared by adding 0.1-1 g Amikacin sulfate salt (Sigma-Aldrich) to 20-40 ml of saline solution). In alternative embodiments, the maturation media may comprise the aforementioned components using different volumes but in the same proportion to each other, e.g., in one embodiment, the

maturation media may comprise 10-40 ml of TCM-199; 1-4 ml of FBS; 20-60 μ l of sodium pyruvate, etc. In a further embodiment, the maturation media comprises the above preparations of TCM-199 Earl's, FBS, pyruvate, chorionic gonadotropin, FSH, estradiol and an antibiotic in the approximate ratio of 9 : 1 : 0.02 : 0.1 : 0.01 : 0.01 : 0.02 by volume, respectively.

2. In Vitro Fertilization. Trim away cumulus cells from matured oocytes. Transfer them to a fertilization dish and return to the CO₂ incubator. Thaw frozen semen straws using standard procedures, centrifuge in 800 μ L of Pure Sperm gradient (Nidacon, Molndal, Sweden), or a percoll or similar gradient at 2500 RPM for 10 minutes to remove egg components, glycerol and other debris. Remove supernatant, leaving a loose pellet of live sperm. Combine pellets using a small amount of fertilization media and repellet at 1500 RPM for 3 minutes. Carefully remove supernatant. Then gently mix the pellet. After determining the desired insemination dose, inseminate the oocytes by adding sperm to the pellet, then culture in a dish and return to the CO₂ incubator for about 18-22 hours.

3. In Vitro Culture. Remove presumptive zygotes from the fertilization dish and transfer into a sterile 1.5 mL eppendorf tube. Allow zygotes to form a loose pellet and remove excess media to form a 1:1 ratio of pellet and solution. Rinse the eppendorf tube with TCM-199, place contents into a dish and wash with BSA media. Then culture presumptive zygotes (discard disfigured oocytes, as well as oocytes with yellow colored cytoplasm or vacuolated cytoplasm) in a dual gas incubator (5% CO₂, 5% O₂) at 38.5°C for about 48 hours.

4. Co-culture. Transfer cleaved zygotes to co-culture dishes comprising the cumulus cells from the mature oocytes and FBS media topped with mineral oil, and incubate in a CO₂ incubator at 38.5°C until needed.

5. Sperm Motility Evaluations by CASA. A comparison of viewing chambers and slides can be done in a variety of IVOS instruments, which for example only can be a Hamilton-Thorne IVOS (Hamilton-Thorne, Beverly, MA). Instrument settings: image capture; frames per second = 60; number of frames = 30; cell detection; minimum contrast = 50; minimum cell size = 5; defaults, cell size = 5; cell intensity = 50; progressive cells, path velocity = 50 μ m/s; straightness \geq 70%; slow cells (μ m/s); average path velocity (VAP, <30 μ m/s), straight-line velocity (VSL, <15 μ m/s). The CASA motility variables measured can be a percentage of total motile sperm (motile), percentage of progressively motile sperm (progressive), VAO, VSL, curvilinear velocity (VCL, μ m/s), average lateral head displacement (ALK, μ m) and the number of times the

sperm head crosses the mean path/s (BCF, Hz), straight-line sperm motility (STR, %), and linear sperm motility (LIN, %). See for instance, Lenz, RW, et al., J Anim Sci (2011) 89:383-388, incorporated by reference herein in its entirety.

A further aspect of the present invention entails the use of a sperm cell sample treated with an OSR in AI. AI in the present invention includes a method whereby a fresh or frozen thawed sperm cell sample is used to inseminate by way of passage of the semen or sperm sample into the female reproductive tract, with or without an accessorizing tool such as an AI gun, catheter or pipette.

Frozen semen samples may be contained in semen straws, which are thawed before the AI procedure using standard methods. In certain embodiments of the invention, the semen straws contain about 0.25-0.5 ml of fluid and are often sufficient for a single insemination.

To increase the number of offspring that a female can produce, embryo transfer techniques (such as MOET) have been developed and are well known to those skilled in the art. Conventional embryo transfer techniques include injection of females with suitable hormones that cause them to produce multiple eggs (oocytes) in a single estrous cycle. This process is often referred to as superovulation. Each female is then artificially inseminated with a sperm cell sample from a male that is either fresh or has been cryopreserved.

In another aspect of the invention, zygotes and/or embryos from artificially inseminated females can be recovered and then cultured and/or cryopreserved/vitrified.

Example 1

One set of semen from each bull was used as a control while to the remaining sets of semen samples were added vitamin B12, as the antioxidant, at respective concentrations of 0.5mg/ml and 0.25mg/ml. For each sample, the same concentration of vitamin B12 was added (i) during the staining process, and (ii) in the catch fluid of the collection vessel. Control samples did not contain vitamin B12. Sperm samples were sorted in "High Purity" mode, and the collected sex-sorted sperm were extended with a cryoextender, which in some cases again contained the same concentration of vitamin B12 and the samples were frozen. Three hours after thawing (which is a standard time frame to conduct quality control assessments on sorted frozen thawed sperm samples) the thawed samples were put through CASA, a machine that provides various data on sperm including motility and progressive motility information. The results are

shown below in Table 1 and the motility and progressive motility are graphically represented in Figure 2.

In the tables below: VAP (average path velocity ($\mu\text{m/s}$)); VSL (straight-line velocity ($\mu\text{m/s}$)); VCL (curvilinear velocity ($\mu\text{m/s}$)); ALH (average lateral head displacement (μm)); BCF (the number of times the sperm head crosses the mean path/s in Hz); STR (percent straight-line sperm motility); LIN (percent linear sperm motility); PIA (percent intact acrosomes); motile (percent motile sperm); and progressive (percent progressively motile sperm).

The two step addition results represent treatments with vitamin B12 present at the same indicated concentration in the catch fluid of the collecting vessel and in the cryoprotectant extender prior to freezing the sample only (2 step-freeze; - + +); the three step addition results indicate that the same concentration of vitamin B12 was added during the staining step, the collecting step (in the catch fluid of the collecting vessel) and in the cryoprotectant extender prior to freezing the sample (3 step). There is no correlation with regard to randomly assigned names such as “Bull A.” Bull A from Example 5 is not the same bull as Bull A from Example 7.

TABLE 1: Motility (2 step and 3 step) (3 hrs Post-Thaw)

	Total cells	Motile (%)	Prog Mot (%)	VAP ($\mu\text{m/s}$)	VSL ($\mu\text{m/s}$)	VCL ($\mu\text{m/s}$)	ALH (μm)	BCF (Hz)	STR (%)	LIN (%)	PIA (%)
Bull 1											
Control	562	59.5	33.5	54	47	95.5	4	21.5	87.5	51	73.5
0.5mg/ml, 2 step F	925	63.5	26	56	45	94	4	23	86.5	49	74
0.25mg/ml, 3 step	815	70.5	40.5	55	48	92	4	23.5	87.5	53	83
Bull 2											
Control	529	54.5	41.5	61	53.5	107.5	4.5	23	87.5	51.5	64
0.5mg/ml, 2 step F	269	70.5	47	77	66	108	4	21.5	85.5	61	84
0.25mg/ml, 3 step	693	67	53.5	68	55	111.5	4.5	24	87	51	79.5
Bull 3											
Control	599	47.5	18	49.5	42.5	84.5	4	20.5	86.5	51.5	52.5
0.5mg/ml, 2 step F	800	74.5	53.5	56	51	98	4	22.5	84.5	52.5	87
0.25mg/ml, 3 step	656	70	48.5	59	50	101	4	24	85.5	51	80
Bull 4											
Control	602	65.5	33.5	53.5	45.5	89.5	4	23.5	86	52.5	72.5
0.5mg/ml, 2 step F	874	81.5	50	60	53	109	5	26	83.5	49	88
0.25mg/ml, 3 step	1059	81	25.5	43	51	88.5	5	23	82.5	47	86

Bull 5											
Control	638	49.5	13	45.5	38.5	86.5	5	18	84	45.5	63.5
0.5mg/ml, 2 step F	842	51	33	50	47	101	5	20.5	84	47	79
0.25mg/ml, 3 step	787	70	40.5	61	48	106.5	5	21.5	84.5	47	80

Example 2

In another series of experiments, the CASA results regarding motility and progressive motility after 4.5 hours after thawing sex-sorted samples against a control are shown below in Table 2. The (2 step-freeze) results indicate that vitamin B12 at the same concentration was present in the catch fluid of the collecting vessel and in the cryoprotectant extender prior to freezing the sample; the (3 step) results indicate that the same concentration of vitamin B12 was added during the staining step, the collecting step (in the catch fluid of the collecting vessel) and in the cryoprotectant extender prior to freezing the sample.

With respect to “Bull A,” the two sets of results shown were obtained on two different days using thawed samples from the same initially sorted batch of sperm. In both cases the concentration of the vitamin B12 was 1mg/ml. For all other bulls in the table below unless otherwise indicated, the concentration of vitamin B12 added was also 1mg/ml.

TABLE 2: Motility (4.5 hrs Post-Thaw)

	Total cells	Motile	Progressive
Bull A			
control	322	38	0
1 mg/ml – 2 step-F	250	41	8
1 mg/ml – 3 step	287	64	37
Bull A (day 2)			
control	328	46	4
1 mg/ml – 2 step-F	433	71	31
1 mg/ml – 3 step	487	64	11
Bull B			
control	298	33	1
1 mg/ml – 2 step-F	316	22	1
1 mg/ml – 3 step	237	59	19
Bull C			
control	403	52	1

1 mg/ml – 2 step-F	432	76	43
1 mg/ml – 3 step	613	62	2
Bull D			
control	644	37	3
1 mg/ml – 3 step	400	59	9
Bull E			
control	653	41	1
1 mg/ml – 3 step	648	52	1
Bull F			
control	638	39	7
0.5 mg/ml – 3 step	761	51	16
0.25 mg/ml – 3 step	730	60	23
Bull G			
control	588	41	13
0.5 mg/ml – 3 step	162	65	57
0.25 mg/ml – 3 step	1003	56	32

Example 3

In an additional experiment, motility and progressive motility were checked 3.75 hours after thawing a sex sorted semen sample treated with the antioxidant. The OSR was not added to the control sample. The semen sample was derived from a single bull. 0.25 mg/ml concentration of vitamin B12 was added to the test sample during the staining step, the collecting step (in the catch fluid of the collecting vessel) and in the cryoprotectant extender prior to freezing the sample. The results are shown in Table 3 below.

TABLE 3: Motility (3.75 hrs Post-Thaw)

	Total cells	Motile (%)	Prog Mot (%)	VAP ($\mu\text{m/s}$)	VSL ($\mu\text{m/s}$)	VCL ($\mu\text{m/s}$)	ALH (μm)	BCF (Hz)	STR (%)	LIN (%)	PIA (%)
Bull 1											
Control	452	7	0	37	28	71	3	16	74	40	41
0.25mg/ml, 3 step	536	39	5	40	34	76	5	17	85	45	70

Example 4

An experiment was designed to test the effect of OSR treated sperm cells on the development of eggs fertilized with those sperm cells. In this experiment, bull semen from two

bulls was sex sorted with flow cytometry, with vitamin B12 present at equal concentrations in the media used to stain the sperm cells, in the catch fluid of the collecting vessel and in the cryoprotectant extender prior to freezing the sex sorted sample (3 step). For each bull, three different concentrations of vitamin B12 were tested: 0.05mg/ml, 0.15mg/ml and 0.25mg/ml. The control samples were not treated with vitamin B12.

Slaughterhouse oocytes were collected and washed 1X with about 3mL Hepes washing media and with 1X with TCM-199 + 10% FBS. The oocytes were then cultured in maturation media for 22 hrs in a CO₂ incubator at 38.5°C. Cumulus cells were trimmed away from matured oocytes, transferred to a fertilization dish, and returned to the CO₂ incubator.

Frozen semen straws were thawed using standard procedures and centrifuged in 800µL of Pure Sperm gradient at 2500 RPM for 10 minutes in order to remove egg, glycerol and other debris. The supernatant was removed, leaving a loose pellet of live sperm. Pellets were combined using a small amount of fertilization media and repelleted at 1500 RPM for 3 minutes. The supernatant was then carefully removed and the pellet gently mixed. After determining the desired insemination dose, the matured oocytes were then inseminated by adding sperm to the pellet, cultured in a dish and returned to the CO₂ incubator for about 18-22 hours.

Presumptive zygotes were removed from the fertilization dish and transferred into a sterile 1.5 ml eppendorf tube. The zygotes were allowed to form a loose pellet and excess media was removed to form a 1:1 ratio of pellet and solution. The eppendorf tube was vortexed for 90 seconds and then rinsed with TCM-199. The contents were placed into a dish and then washed with BSA media. The presumptive zygotes were then cultured in a dual gas incubator (5% CO₂, 5% O₂) at 38.5°C for about 48 hours. Cleaved zygotes were then transferred to co-culture dishes comprising the cumulus cells from the mature oocytes and FBS media topped with mineral oil and incubated in a CO₂ incubator at 38.5°C.

Embryos were observed 7 days after IVF to check: Zyg (the number of zygotes put into culture); 4-2C (the number of zygotes that underwent the 2 cell to 4 cell transition 48 hours after IVF); 8C (the number of zygotes with 8 cells 48 hours after IVF); 8C% (the percentage of zygotes having 8 cells 48 hours after IVF); % Clv (percent cleaved 48 hours after IVF); C1 (number of expanded and hatching and hatched blastocysts 7 days after IVF); C1- (number of blastocysts 7 days after IVF); and C2 (number of early blastocysts and compact morulas 7 days after IVF), Total Embs (total number of blastocysts = C1+ C1- + C2); Blast % (percent of

cultured zygotes resulting in blastocyst formation); Hatch # (the number of embryos shedding the zona palucida in preparation for implantation observed at 8.5 days after IVF); and Hatch % (percentage of embryos that shed the zona). The results are provided in Table 4 below.

TABLE 4: IVF - Embryo / Fertilization (3 step)

	Zyg	4-2C	8C	8C%	% Clv	C1	C1-	C2	Total Embs	Blast %	Hatch #	Hatch %
Bull A												
Control	96	36	8	8.3	45.8	1	0	5	6	6.3	2	33.3
Control	68	19	7	10.3	38.2	0	0	2	2	2.9	0	0.0
Control	91	31	19	20.9	54.9	2	3	10	15	16.5	5	33.3
Total/Avg	255	86	34	(13.3)	(47.1)	3	3	17	23	(9.0)	7	(30.4)
0.05mg/ml	87	20	3	3.4	26.4	0	0	1	1	1.1	0	0.0
0.05mg/ml	95	26	9	9.5	36.8	1	0	1	2	2.1	1	50.0
0.05mg/ml	94	20	11	11.7	33.0	0	3	1	4	4.3	1	25.0
Total/Avg	276	66	23	(8.3)	(32.2)	1	3	3	7	(2.5)	2	(28.6)
0.15mg/ml	89	25	4	4.5	32.6	0	1	4	5	5.6	0	0.0
0.15mg/ml	90	29	9	10.0	42.2	1	0	4	5	5.6	3	60.0
0.15mg/ml	91	24	6	6.6	33.0	2	1	4	7	7.7	3	42.9
Total/Avg	270	78	19	(7.0)	(35.9)	3	2	12	17	(6.3)	6	(35.3)
0.25mg/ml	91	33	6	6.6	42.9	0	2	3	5	5.5	2	40.0
0.25mg/ml	93	38	20	21.5	62.4	4	2	10	16	17.2	10	62.5
0.25mg/ml	91	26	16	17.6	46.2	2	3	10	15	16.5	6	40.0
Total/Avg	275	97	42	(15.3)	(50.5)	6	7	23	36	(13.1)	18	(50.0)
Bull B												
Control	91	15	35	38.5	54.9	3	3	8	14	15.4	9	64.3
Control	90	25	29	32.2	60.0	4	5	9	18	20.0	10	55.6
Control	92	20	33	35.9	57.6	7	6	12	25	27.2	15	60.0
Total/Avg	273	60	97	(35.5)	(57.5)	14	14	29	57	(20.9)	34	(59.6)
0.05mg/ml	90	18	40	44.4	64.4	2	4	13	19	21.1	9	47.4
0.05mg/ml	92	23	27	29.3	54.3	4	2	9	15	16.3	7	46.7
0.05mg/ml	93	22	27	29.0	52.7	5	3	13	21	22.6	8	38.1
Total/Avg	275	63	94	(34.2)	(57.1)	11	9	35	55	(20.0)	24	(43.6)
0.15mg/ml	96	21	38	39.6	61.5	6	7	10	23	24.0	17	73.9
0.15mg/ml	93	32	14	15.1	49.5	2	3	6	11	11.8	6	54.5
0.15mg/ml	100	21	29	29.0	50.0	4	4	14	22	22.0	9	40.9
Total/Avg	289	74	81	(28.0)	(53.6)	12	14	30	56	(19.4)	32	(57.1)

0.25mg/ml	92	24	34	37.0	63.0	5	3	11	19	20.7	14	73.7
0.25mg/ml	96	31	23	24.0	56.3	1	3	3	7	7.3	5	71.4
Total/Avg	188	55	57	(30.3)	(59.6)	6	6	14	26	(13.8)	19	(73.1)

Example 5

A similar experiment as done in Example 4 was done to test the effect of OSR treated sperm cells on the development of eggs fertilized using a higher concentration of the antioxidant, comparing it to one of the earlier used concentrations. Semen samples from two bulls of different breeds (one Holstein; one Jersey) were sex sorted using flow cytometry, again using vitamin B12 as the antioxidant, present at equal concentrations during staining, in the catch fluid of the collecting vessel and in the cryoprotectant extender prior to freezing the sex sorted sample (3 step). For each bull, the two concentrations of vitamin B12 tested were: 0.5mg/ml and 0.25mg/ml. The control samples were not treated with vitamin B12. All experimental steps were done the same as in Example 4. The results are shown in Table 5 below.

TABLE 5: IVF - Embryo Fertilization (3 step)

	Zyg	4-2C	8C	8C%	% Clv	C1	C1-	C2	Total Embs	Blast %	Hatch #	Hatch %
Bull A (Holstein)												
Control	91	25	35	38.5	65.9	3	2	4	9	9.9	3	33.3
Control	93	40	19	20.4	63.4		1	2	3	3.2	0	0.0
Control	98	25	25	25.5	51.0	3	6	5	14	14.3	6	42.9
Total/Avg	282	90	79	28.0	(60.1)	6	9	11	26	(9.2)	9	(34.6)
0.25mg/ml	97	25	39	40.2	66.0	6	9	5	20	20.6	8	40.0
0.25mg/ml	97	34	30	30.9	66.0	5	6	5	16	16.5	4	25.0
0.25mg/ml	97	23	33	34.0	57.7	6	7	6	19	19.6	9	47.4
Total/Avg	291	82	102	35.1	(63.2)	17	22	16	55	(18.9)	21	(38.2)
0.5mg/ml	94	25	34	36.2	62.8	0	3	3	6	6.4	1	16.7
0.5mg/ml	95	29	30	31.6	62.1	1	7	7	15	15.8	4	26.7
0.5mg/ml	93	18	35	37.6	57.0	5	7	8	20	21.5	11	55.0
Total/Avg	282	72	99	35.1	(60.6)	6	17	18	41	(14.5)	16	(39.0)
Bull B (Jersey)												
Control	97	39	39	40.2	80.4	5	5	3	13	13.4	7	53.8
Control	100	22	12	12.0	34.0	4	5		9	9.0	2	22.2
Control	100	22	29	29.0	51.0	2	5	1	8	8.0	3	37.5

Total/Avg	297	83	80	26.9	(55.1)	11	15	4	30	(10.1)	12	(40.0)
0.25mg/ml	94	25	45	47.9	74.5	5	9	4	18	19.1	12	66.7
0.25mg/ml	99	36	20	20.2	56.6	7	6	6	19	19.2	6	31.6
0.25mg/ml	99	17	46	46.5	63.6	5	7	8	20	20.2	9	45.0
Total/Avg	292	78	111	38.0	(64.8)	17	22	18	57	(19.5)	27	(47.4)
0.5mg/ml	100	40	34	34.0	74.0	4	6	1	11	11.0	5	45.5
0.5mg/ml	95	31	24	25.3	57.9	5	11	7	23	24.2	6	26.1
0.5mg/ml	99	15	46	46.5	61.6	8	5	5	18	18.2	9	50.0
Total/Avg	294	86	104	35.4	(64.5)	17	22	13	52	(17.7)	20	(38.5)

Example 6

Another experiment similar to Examples 4 and 5 was performed to test the reproducible effect of OSR treated sperm cells regarding a single bull by monitoring the development of embryos. Bull A (Holstein) was sampled three different times; Bull B was sampled five different times; Bull C only one time; all semen samples were subjected to standard sex sorting procedures using flow cytometry with vitamin B12 as the OSR at 0.25 mg/ml during the steps of staining, collection in the catch fluid and prior to cryopreservation (3 step). The control samples were not treated with vitamin B12. All experimental steps were done the same as in Example 4. The results are provided in Table 6, below.

TABLE 6: IVF (3 step) - Reproducibility

Bull A (Holstein)	Zyg	4-2C	8C	8C%	% Clv	C1	C1-	C2	Total Embs	Blast %	Freeze %	Hatch %
Trial 1												
Control	507	85	119	23.5	40.2	34	19	31	84	16.6	10.5	
0.25mg/ml	434	92	100	23.0	44.2	27	14	44	85	(19.6)	9.4	
Trial 2												
Control	993	238	287	28.9	52.9	54	26	86	166	16.7	8.1	
0.25mg/ml	884	204	222	25.1	48.2	81	36	128	245	(27.7)	13.2	
Trial 3												
Control	907	209	215	23.7	46.7	70	27	90	187	20.6	10.7	
0.25mg/ml	1053	230	285	27.1	48.9	83	39	129	251	(23.8)	11.6	
Average - Control										(18.2)	(9.6)	
Average - 0.25 mg/ml										(24.5)	(11.8)	

Bull B (Holstein)	Zyg	4-2C	8C	8C%	% Clv	C1	C1-	C2	Total Embs	Blast %	Freeze %	Hatch %
Trial 1												
Control	507	85	119	23.5	40.2	34	19	31	84	16.6	10.5	
0.25mg/ml	434	92	100	23.0	44.2	27	14	44	85	(19.6)	9.4	
Trial 2												
Control	993	238	287	28.9	52.9	54	26	86	166	16.7	8.1	
0.25mg/ml	884	204	222	25.1	48.2	81	36	128	245	(27.7)	13.2	
Trial 3												
Control	907	209	215	23.7	46.7	70	27	90	187	20.6	10.7	
0.25mg/ml	1053	230	285	27.1	48.9	83	39	129	251	(23.8)	11.6	
Trial 4												
Control	550	122	177	32.2	54.4	12	19	56	87	15.8	5.6	
0.25mg/ml	595	124	183	30.8	51.6	12	8	52	72	(12.1)	3.4	
Trial 5												
Control	596	107	159	26.7	44.6	31	21	83	135	22.7	8.7	
0.25mg/ml	636	137	185	29.1	50.6	27	24	79	130	(20.4)	8.0	
Average - Control										(18.5)	(8.8)	
Average - 0.25 mg/ml										(21.7)	(9.7)	

Bull C	Zyg	4-2C	8C	8C%	% Clv	C1	C1-	C2	Total Embs	Blast %	Freeze %	Hatch %
Trial 1												
Control	454	113	265	58.4	83.3	21	17	49	87	(19.2)	(8.4)	
0.25mg/ml	509	104	335	65.8	86.2	31	27	62	120	(23.6)	(11.4)	

Example 7

A larger scale experiment was done to further test the reproducibility similar to what was done in Examples 6 and 7, but testing five bulls each three separate times. Semen samples from five bulls were sampled and sex sorted using flow cytometry in accordance with the earlier procedures and treated with 0.25 mg/ml vitamin B12 as the OSR (3 step). The control samples were not treated with vitamin B12.

TABLE 7: Averaged Effect (Holstein and Jersey Mix)

	Zyg	4-2C	8C	8C%	% Clv	C1	C1-	C2	Total Embs	Blast %	Hatch #	Hatch %
Control-A1	993	238	287	28.9	52.9	54	26	86	166	16.7		
Control-A2	507	85	119	23.5	40.2	34	19	31	84	16.6		
Control-A3	907	209	215	23.7	46.7	70	27	90	187	20.6		
Control-B1	96	36	8	8.3	45.8	1	0	5	6	6.3	2	33.3
Control-B2	68	19	7	10.3	38.2	0	0	2	2	2.9	0	0.0
Control-B3	91	31	19	20.9	54.9	2	3	10	15	16.5	5	33.3
Control-C1	91	15	35	38.5	54.9	3	3	8	14	15.4	9	64.3
Control-C2	90	25	29	32.2	60.0	4	5	9	18	20.0	10	55.6
Control-C3	92	20	33	35.9	57.6	7	6	12	25	27.2	15	60.0
Control-D1	97	39	39	40.2	80.4	5	5	3	13	13.4	7	53.8
Control-D2	100	22	12	12.0	34.0	4	5		9	9.0	2	22.2
Control-D3	100	22	29	29.0	51.0	2	5	1	8	8.0	3	37.5
Control-E1	91	25	35	38.5	65.9	3	2	4	9	9.9	3	33.3
Control-E2	93	40	19	20.4	63.4		1	2	3	3.2	0	0.0
Control-E3	98	25	25	25.5	51.0	3	6	5	14	14.3	6	42.9
Total/Avg	3514	851	911	25.9	(50.1)	192	113	268	573	(16.3)	62	(10.8)
0.25 -A1	884	204	222	25.1	48.2	81	36	128	245	27.7		
0.25 -A2	434	92	100	23.0	44.2	27	14	44	85	19.6		
0.25 -A3	1053	230	285	27.1	48.9	83	39	129	251	23.8		
0.25 -B1	91	33	6	6.6	42.9	0	2	3	5	5.5	2	40.0
0.25 -B2	93	38	20	21.5	62.4	4	2	10	16	17.2	10	62.5
0.25 -B3	91	26	16	17.6	46.2	2	3	10	15	16.5	6	40.0
0.25 -C1	92	24	34	37.0	63.0	5	3	11	19	20.7	14	73.7
0.25 -C2	96	31	23	24.0	56.3	1	3	3	7	7.3	5	71.4
0.25 -C3												
0.25 -D1	94	25	45	47.9	74.5	5	9	4	18	19.1	12	66.7
0.25 -D2	99	36	20	20.2	56.6	7	6	6	19	19.2	6	31.6
0.25 -D3	99	17	46	46.5	63.6	5	7	8	20	20.2	9	45.0
0.25 -E1	97	25	39	40.2	66.0	6	9	5	20	20.6	8	40.0
0.25 -E2	97	34	30	30.9	66.0	5	6	5	16	16.5	4	25.0

0.25 –E3	97	23	33	34.0	57.7	6	7	6	19	19.6	9	47.4
Total/Avg	3417	838	919	26.9	(51.4)	237	146	372	755	(22.1)	85	(11.3)

Example 8

In an additional experiment, post-thaw motility and progressive motility were checked using CASA at 0, 3 and 5 hours after thawing sex sorted semen samples (sorted using flow cytometry) treated with vitamin B12 as the antioxidant. The OSR was not added to the control samples. The semen samples were derived from two Holstein bulls. 0.25 mg/ml concentration of vitamin B12 was added to the test samples during the staining step, the collecting step (in the catch fluid of the collecting vessel) and in the cryoprotectant extender prior to freezing the sample (3 step). The results are shown in Table 8 below.

TABLE 8: Post-Thaw Motility (3 step)

Bull A	Total cells	Motile (%)	Prog Mot (%)	VAP ($\mu\text{m/s}$)	VSL ($\mu\text{m/s}$)	VCL ($\mu\text{m/s}$)	ALH (μm)	BCF (Hz)	STR (%)	LIN (%)	PIA (%)
0 hr Post-Thaw:											
Bull A - Control	1884	77	53	107	81	211	9	23	76	40	
Bull A - Control	1275	74	51	99	75	198	9	24	77	41	90
Average		(76)	(52)	103	78	205	9	24	77	41	
Bull A – 0.25	1074	73	51	89	68	183	8	26	77	40	
Bull A – 0.25	1519	69	50	101	78	195	8	27	78	43	90
Average		(71)	(51)	95	73	189	8	27	78	42	
3 hr Post-Thaw:											
Bull A - Control	1064	48	3	38	29	76	6	14	77	40	56
Bull A - Control	683	53	7	44	36	80	5	17	84	46	63
Average		(50)	(5)	41	32.5	78	5.5	15.5	80.5	43	59.5
Bull A – 0.25	870	64	22	48	39	84	8	14	77	41	86
Bull A – 0.25	978	46	7	41	31	83	8	14	77	38	76
Average		(55)	(15)	45	35	84	8	14	77	40	81
5 hr Post-Thaw:											
Bull A - Control	903	40	8	14	11	25	3	7	14	9	52
Bull A - Control	517	15	1	12	10	18	2	10	17	18	60
Average		(27.5)	(4.5)	13	10.5	21.5	2.5	8.5	15.5	13.5	56
Bull A – 0.25	708	61	26	17	17	23	2	6	13	12	79

Bull A – 0.25	747	34	7	20	16	28	3	8	14	13	72
Average		(47.5)	(16.5)	18.5	16.5	25.5	2.5	7	13.5	12.5	75.5

Bull B	Total cells	Motile (%)	Prog Mot (%)	VAP ($\mu\text{m/s}$)	VSL ($\mu\text{m/s}$)	VCL ($\mu\text{m/s}$)	ALH (μm)	BCF (Hz)	STR (%)	LIN (%)	PIA (%)
0 hr Post-Thaw:											
Bull B - Control	1878	73	57	88	73	153	7	27	83	49	
Bull B - Control	1706	72	54	83	69	142	6	28	84	51	90
Average		(73)	(55.5)	85.5	71	148	7	28	84	50	
Bull B – 0.25	1804	79	58	85	70	145	6	28	83	51	
Bull B – 0.25	1150	79	54	81	67	143	6	29	84	51	90
Average		(79)	(56)	83	69	144	6	29	84	51	
3 hr Post-Thaw:											
Bull B - Control	666	30	10	39	25	80	8	16	66	33	60
Bull B - Control	670	50	12	45	37	85	6	16	82	44	72
Average		(50)	(11)	42	31	82.5	7	16	74	38.5	66
Bull B – 0.25	928	56	18	50	39	96	6	18	80	42	83
Bull B – 0.25	772	42	12	46	37	89	6	18	80	42	82
Average		(49)	(15)	48	38	93	6	18	80	42	82.5
5 hr Post-Thaw:											
Bull B - Control	539	0	0	40	16	52	0	26	40	31	46
Bull B - Control	609	0	0	35	26	44	0	71	75	39	61
Average		(0)	(0)	37.5	21	48	0	48.5	57.5	35	53.5
Bull B – 0.25	902	43	4	41	28	85	7	14	70	34	83
Bull B – 0.25	721	21	0	38	21	70	4	14	57	32	73
Average		(32)	(2)	39.5	24.5	77.5	5.5	14	63.5	33	78

Example 9

In an additional experiment, motility and progressive motility were checked at 0 hours and 3 hours after thawing sex sorted semen samples (sorted using flow cytometry) treated with the antioxidant, vitamin B12. The OSR was not added to the control sample. The semen samples were derived from two different breeds of bull, one a Holstein the other Texas Longhorn. 0.25 mg/ml concentration of vitamin B12 was added to the test samples either (i) during the staining step (1 step-stain); (ii) the staining step and the collecting step (in the catch fluid of the collecting vessel) (2 step-stain); (iii) in the staining step, the collecting step and the freezing step (in the

cryoprotectant extender prior to freezing the sample) (3 step) – Table 9 (A) for 3 hr, and (B) for 0 hr; or (iv) only prior to the cryopreservation step (1 step-freeze) – Table 9 (C) for 3 hr.

TABLE 9 (A): 3 hr Post-Thaw Motility (3 step; 2 step-stain; 1 step-stain)

Bull 1 (TL) 3 hr Post-Thaw	Total cells	Motile (%)	Prog Mot (%)	VAP (µm/s)	VSL (µm/s)	VCL (µm/s)	ALH (µm)	BCF (Hz)	STR (%)	LIN (%)	PIA (%)
Control		(12)	(3)	42	35	77	3	19	83	46	23
3 step (+++)		42	25	55	47	101	5	23	84	48	73
2 step-stain (+ + -)		25	9	47	41	85	5	21	87	49	47
1 step-stain (+ - -)		37	23	56	47	84	5	16	85	57	52

Bull 2 (Jersey) 3 hr Post-Thaw	Total cells	Motile (%)	Prog Mot (%)	VAP (µm/s)	VSL (µm/s)	VCL (µm/s)	ALH (µm)	BCF (Hz)	STR (%)	LIN (%)	PIA (%)
Control		(72)	(63)	70	59	108	5	19	85	56	72
3 step (+++)		75	70	81	74	124	5	22	88	58	80
2 step-stain (+ + -)		57	35	60	50	105	5	19	84	48	78
1 step-stain (+ - -)		47	32	59	49	98	5	19	84	51	71

Average	Total cells	Motile (%)	Prog Mot (%)	VAP (µm/s)	VSL (µm/s)	VCL (µm/s)	ALH (µm)	BCF (Hz)	STR (%)	LIN (%)	PIA (%)
Avg - Control		(42)	(33)	56	47	92	4	19	84	51	48
3 step (+++)		58	47	68	60	112	5	23	86	53	77
2 step-stain (+ + -)		41	22	53	45	95	5	20	85	48	63
1 step-stain (+ - -)		42	28	57	48	91	5	18	85	54	61

TABLE 9 (B) – 0 hr Post-Thaw Motility (3 step; 2 step-stain; 1 step-stain)

Bull 1 (TL) 0 hr Post-Thaw	Total cells	Motile (%)	Prog Mot (%)	VAP (µm/s)	VSL (µm/s)	VCL (µm/s)	ALH (µm)	BCF (Hz)	STR (%)	LIN (%)	PIA (%)
Control		(58.5)	(49.5)	93.5	81.0	161.5	7.0	26.0	86.5	52.5	
3 step (+++)		76	60	89.5	79.5	154.5	7.0	27.5	89.0	56.5	
2 step-stain (+ + -)		57	48	96.0	84.0	168.0	7.0	25.5	87.5	52.0	
1 step-stain (+ - -)		60.5	55	95.0	83.5	167.0	7.0	26.5	88.5	52.0	

Bull 2 (Jersey) 0 hr Post-Thaw	Total cells	Motile (%)	Prog Mot (%)	VAP (µm/s)	VSL (µm/s)	VCL (µm/s)	ALH (µm)	BCF (Hz)	STR (%)	LIN (%)	PIA (%)
Control		(79)	(68)	105.0	89.0	179.0	7.0	26.0	86.0	53.0	
3 step (+++)		70	57.7	94.5	82.0	165.5	6.5	30.0	86.5	52.0	

2 step-stain (+ + -)		74	67	97.0	85.0	170.0	7.0	27.0	88.0	52.0	
1 step-stain (+ - -)		80	71	104.0	88.0	189.0	8.0	26.0	85.0	49.0	

TABLE 9 (C) – 3 hr Post-Thaw Motility (1 step-freeze)

Bull 3 3 hr Post-Thaw	Total Cells	Motile (%)	Prog Mot (%)	VAP ($\mu\text{m/s}$)	VSL ($\mu\text{m/s}$)	VCL ($\mu\text{m/s}$)	ALH (μm)	BCF (Hz)	STR (%)	LIN (%)	PIA (%)
Control	418	20	0	38	26	67	14	12			63
Control	238	29	0	35	23	53	0	14			59
Avg - Control	656	(24.5)	(0)	36.5	24.5	60	7	13			61
1 step-freeze (- - +)	384	50	10	43	35	80	5	17			63
1 step-freeze (- - +)	385	59	17	48	40	86	5	19			83
1 step-freeze (- - +)	210	32	4	41	31	75	6	13			67
1 step-freeze (- - +)	301	45	11	45	33	81	6	13			85
Avg – 1 step-frz	1280	(46.5)	(10.5)	44.25	34.75	80.5	5.5	15.5			74.5

Example 10

An additional experiment was conducted to assess the pregnancy rate of female bovines inseminated with sorted sperm cell samples treated with an antioxidant. Semen samples from two bulls were sex sorted using the protocol described above. 0.25 mg/ml concentration of vitamin B12 was added to the test samples during the staining step, the collecting step (in the catch fluid of the collecting vessel) and the freezing step (3 step).

Frozen semen straws containing sex sorted sperm cell samples were thawed using standard procedures. An artificial insemination (AI) gun was warmed as needed to approach body temperature of the recipient, and a straw was placed in the barrel of the insemination gun. The sealed end of the straw was cut off and a plastic sheath was placed over the straw and gun for hygienic purposes. The female was previously placed in a restraining shoot for insemination. The gun was threaded through the vagina and cervix and semen distributed in the uterine body. 384 females were inseminated, each inseminated with a single sperm cell dose, and each dose containing 2.1 million sperm cells in 0.25 ml. Pregnancy checks were made 33-40 days post insemination with an ultrasound machine. The results are shown in Table 10 below.

TABLE 10: Pregnancies (3 step)

		Inseminations	Percent Pregnancy
Bull A	Control	87	32.8
	0.25mg/ml	100	35.6
Bull B	Control	99	30.9
	0.25mg/ml	98	27.0
Total/Average	Control	186	(31.9)
Total/Average	0.25mg/ml	198	(31.3)

Example 11

Additional pregnancy field trials were performed using the sex-sorted semen treated with vitamin B12 at 0.25 mg/ml added to the test samples during the staining step, the collecting step and again in the freezing step (3-step), as done in Example 10 was evaluated another time looking using semen from five different Holstein bulls. Each semen sample was split into control and vitamin B12 (0.25 mg/ml) treatment groups, and later inseminated into primiparous recipient heifers. Pregnancy checks were made 33-40 days post insemination using ultrasound. The results are shown in Table 11 below.

TABLE 11: Pregnancies (3 step)

	Antioxidant	Inseminations	Percent Pregnancy
Bull A	Control		27.9
	0.25 mg/ml		28.4
Bull B	Control		26.1
	0.25 mg/ml		28.0
Bull C	Control		32.8
	0.25 mg/ml		35.6
Bull D	Control		26.0
	0.25 mg/ml		30.7
Bull E	Control		50.0
	0.25 mg/ml		57.0
Total/Average	Control	499	(32.6)
Total/Average	0.25 mg/ml	374	(35.9)

Example 12

The levels of DNA fragmentation were also screened using a DNA fragmentation 'Halomax for animals' kit (Halotech DNA, sl, Madrid, Spain) to determine if there were any advantageous effects of using the antioxidants during the staining and processing of sex-sorted

sperm. Two different breeds of cattle, Jersey and Holstein, were examined using two different concentrations of antioxidant, 0.25 mg/ml and 0.5 mg/ml of vitamin B12 with the 3 step protocol adding the same concentration of OSR during cell staining, in the collection catch fluid and prior to cryopreservation. One of the bulls was used to evaluate the effect of addition or omission of OSR at one or more of the sperm sorting steps. Motility and the level of DNA fragmentation were both recorded. The results are shown in Table 12 below.

TABLE 12: DNA Fragmentation (1 step-stain, 2 step, 3 step)

	% Motility		% DNA Fragmentation		
	0 hr	3 hr	0 hr	24 hr	48 hr
Bull A (Jersey)					
Control	57	17	1	1	1.7
0.25mg/ml	72	51	0.3	0.3	0.7
0.5mg/ml	60	42	0.3	0.7	1.3
Bull B (Holstein)					
Control	62	32	0.3	0.3	0.7
0.25mg/ml	67	32	0	0.3	0.3
0.5mg/ml	79	48	0.3	0.3	0.7

	% Motility		% DNA Fragmentation		
	0 hr	3 hr	0 hr	24 hr	48 hr
Bull C (Jersey)					
Trial 1					
Control	79	72	1	1	1
3 step (+++)	70	75	0	0.3	0.3
2 step-stain (+ + -)	74	57	0.3	1	1
1 step-stain (+ - -)	80	47	0.7	1	1.3
Trial 2					
Control	59	12	0.3	1.7	1.7
3 step (+++)	76	42	0.3	0.3	0.7
2 step-stain (+ + -)	57	25	0.3	0.7	0.7
1 step-stain (+ - -)	61	37	0.7	1	1

Example 13

The effect of OSR on motility was evaluated as a function of the concentration of the sex-sorted sperm in the frozen straw. Tests were performed using vitamin B12 as the OSR at three different concentrations of the antioxidant: 0.15 mg/ml; 0.25 mg/ml and 0.35 mg/ml; all were

added to the test samples during the staining step, the collecting step and again in the freezing step (3-step), as done in Example 8. Holstein sperm was evaluated at three sperm cell concentrations based upon total number of sperm per straw: 1 million sperm/straw; 2.1 million sperm/straw; and 5 million sperm/straw. Motility was recorded 3 hr post-thaw.

A Jersey sperm sample was also evaluated in the same manner using 0.15 mg/ml or 0.25 mg/ml vitamin B12 at each of the three stages (3 step), but only at the 2.1 million sperm/straw concentration. The results are shown in Table 13.

TABLE 13: Frozen Sperm Cell Concentration (3 step)

(Holstein)	Motile	Prog	VAP	VSL	VCL	ALH	BCF	STR	LIN	PIA
1M/straw										
Control	20	4	40	32	76	3	15	78	42	43
.15mg/ml	48	18	48	42	81	4	12	88	53	66
.25 mg/ml	48	29	55	47	92	4	22	87	53	58
.35 mg/ml	65	46	58	51	94	4	23	88	55	70
2.1M/straw										
Control	28	2	39	33	73	6	16	85	46	41
.15mg/ml	49	10	44	38	79	5	18	86	48	72
.25 mg/ml	48	18	46	40	81	5	20	87	50	76
.35 mg/ml	46	30	58	51	99	5	23	88	53	60
5M/straw										
Control	20	1	39	29	69	7	13	74	43	46
.25mg/ ml	24	2	41	28	69	7	14	70	42	68
.35mg/ ml	28	3	41	32	68	7	14	69	43	69
.5mg/ ml	14	3	43	30	71	6	15	70	43	50
(Jersey)										
2.1M/straw										
Control	25	2	37	28	55	2	11	76	52	53
.15mg/ml	25	4	42	35	75	6	15	84	47	63
.25mg/ml	48	20	51	43	87	5	20	85	50	78

Example 14

The effect of a different OSR on bovine sperm motility was evaluated after zero hour and a three hour post-thaw period. The OSR, α -tocopheryl, a form of Vitamin E, was purchased as

'polyoxyethanyl- α -tocopheryl sebacate' in a 15% stock solution (Aldrich). Tests were performed using α -tocopheryl as the OSR, at three different concentrations: 0.01 mg/ml; 0.1 mg/ml and 0.5 mg/ml; all were added to the test samples during the staining step, the collecting step and again in the freezing step (3-step), as done in the prior Examples. Sex-sorted Holstein sperm was evaluated using a standard sperm concentration of 2.1 million sperm/straw processed from three separate bulls. Motility of the treated samples were compared to untreated controls and recorded at 0 hr and 3 hr post-thaw.

TABLE 14: Motility with α -tocopheryl (vitamin E) (3 step)

	Total cells	Motile	Prog	VAP	VSL	VCL	ALH	BCF	STR	LIN
Holstein										
0 hr Post-Thaw										
Bull A										
Control	548	56	25	75	52	151	7	22	74	39
0.01	617	72	17	100	49	201	10	20	56	27
0.1	458	73	33	99	62	217	9	22	66	32
0.5	424	63	36	97	68	214	9	22	72	34
Bull B										
Control	548	56	25	75	52	151	7	22	74	39
0.01	617	72	17	100	49	201	10	20	56	27
0.1	458	73	33	99	62	217	9	22	66	32
0.5	424	63	36	97	68	214	9	22	72	34
Bull C (1)										
Control	280	50	30	66	51	140	7	20	78	39
0.01	530	59	39	89	68	188	10	20	76	38
0.1	518	63	35	86	61	196	10	20	72	33
0.5	269	30	17	75	53	179	8	22	72	31
Bull C (2)										
Control	364	23	12	65	54	116	5	25	82	49
0.01	347	36	27	86	78	140	6	26	90	57
0.1	822	27	18	84	75	149	6	25	88	52
0.5	764	29	18	74	64	130	7	28	87	55
Holstein										
3 hr Post-Thaw										
A-toc	Total cells	Motile	Prog	VAP	VSL	VCL	ALH	BCF	STR	LIN
Bull A										
Control	260	25	6	39	33	71	5	16	83	47

0.01	253	64	20	51	42	92	5	21	84	49
0.1	297	62	32	54	46	101	5	22	86	48
0.5	235	54	29	60	51	106	5	24	85	49
Bull B										
Control	309	29	8	46	37	83	6	19	82	46
0.01	126	28	9	54	39	103	4	21	76	41
0.1	154	14	4	56	36	100	6	18	73	38
0.5	151	36	10	57	41	104	5	22	77	44
Bull C (1)										
Control	200	14	2	40	33	77	5	18	83	44
0.01	222	19	3	41	38	60	4	29	93	70
0.1	155	15	5	49	41	94	7	21	84	45
0.5	82	26	13	50	44	89	5	18	87	50
Bull C (2)										
Control	207	2	0	19	15	26	1	11	73	27
0.01	270	6	0	35	21	55	0	13	60	39
0.1	658	4	0	38	29	63	1	8	76	46
0.5	278	2	0	37	21	64	0	14	55	33

Example 15

The effect of a third OSR on bovine sperm motility was evaluated after zero hour, three hour and six hour post-thaw periods. Alpha-ketoglutarate (AKG) was freshly made and used at three different concentrations: 0.25 mg/ml; 0.35 mg/ml and 0.45 mg/ml; all were added to the test samples during the staining step, the collecting step and again in the freezing step (3-step), as done in the prior Examples. Sex-sorted Holstein and Jersey bovine sperm were evaluated using a standard concentration of 2.1 M sperm/straw. Motility of the treated samples was compared to untreated controls at 0 hr, 3 hr and 6 hr post-thaw.

TABLE 15: Alpha-keto Glutarate (AKG) (3 step)

Holstein – 0 hr	Motile	Prog	VAP	VSL	VCL	ALH	BCF	STR	LIN	
control	41	16	69	44	143	8	21	66	34	
.25 mg/ ml	91	75	104	81	185	8	27	82	48	
.35 mg/ ml	80	65	94	80	165	7	29	85	51	
.45 mg/ ml	86	75	98	88	162	7	30	89	57	
Holstein - 3hr	Motile	Prog	VAP	VSL	VCL	ALH	BCF	STR	LIN	PIA
control	4	0	36	24	53	0	10	67	48	44
.25 mg/ ml	77	60	99	79	176	7	26	81	45	89
.35 mg/ ml	63	48	85	70	145	6	25	83	50	80

.45 mg/ ml	60	56	94	80	145	5	24	85	56	80
------------	----	----	----	----	-----	---	----	----	----	----

Holstein - 3 hr	Motile	Prog	VAP	VSL	VCL	ALH	BCF	STR	LIN	PIA
control	30	7	40	30	68	3	13	74	46	44
.25 mg/ ml	71	55	96	77	169	6	26	81	47	89
.35 mg/ ml	64	38	69	57	117	5	21	84	50	80
.45 mg/ ml	60	50	90	75	144	6	25	84	53	80

Holstein - 6 hr	Motile	Prog	VAP	VSL	VCL	ALH	BCF	STR	LIN	PIA
control	4	0	38	23	55	0	12	61	42	56
.25 mg/ ml	36	7	44	33	87	6	17	76	39	73
.35 mg/ ml	58	7	42	32	80	7	16	76	40	85
.45 mg/ ml	52	22	55	46	96	5	22	82	48	79

Holstein - 6 hr	Motile	Prog	VAP	VSL	VCL	ALH	BCF	STR	LIN	PIA
control	4	0	38	23	55	0	12	61	42	56
.25 mg/ ml	36	7	44	33	87	6	17	76	39	73
.35 mg/ ml	58	7	42	32	80	7	16	76	40	85
.45 mg/ ml	52	22	55	46	96	5	22	82	48	79

Jersey - 0 hr	Motile	Prog	VAP	VSL	VCL	ALH	BCF	STR	LIN
control	72	60	82	72	141	6	25	87	53
.25 mg/ ml	67	51	83	68	152	7	24	83	48
.35 mg/ ml	57	43	79	63	146	6	25	82	47
.45 mg/ ml	81	66	81	70	133	6	27	87	56

Jersey - 3 hr	Motile	Prog	VAP	VSL	VCL	ALH	BCF	STR	LIN	PIA
control	13	1	36	24	65	2	14	66	38	42
.25 mg/ ml	33	16	65	49	117	5	24	79	46	62
.35 mg/ ml	26	10	59	46	110	6	25	80	45	54
.45 mg/ ml	59	25	67	50	66	6	25	78	45	71

Example 16

The effect of combining two antioxidants on bovine sperm motility was evaluated after zero hour, three hour and six hour post-thaw periods. Vitamin B12 was used at 0.25 mg/ml and fresh alpha-ketoglutarate (AKG) was used at 0.35 mg/ml. Either vitamin B12 or AKG or both treatments were added at the designated concentrations during the staining step, the collecting step and again in the freezing step (3-step), as done earlier. Sex-sorted sperm from three Jersey bulls were evaluated using standard 2.1 M sperm/straw. Motility of the treated samples was compared to untreated controls at 0 hr, 3 hr and 6 hr post-thaw.

TABLE 16: Combination AKG, Vitamin B12, and Combination (3 step)

Jersey 1 - 0hr	Motile	PROG	VAP	VSL	VCL	ALH	BCF	STR	LIN
Control	75	67	99	87	162	6	30	88	56
B12 - 0.25 mg/ml	88	78	97	87	157	6	33	89	58
AKG - 0.35 mg/ml	87	75	93	81	148	6	31	88	57
COMBO	78	69	93	83	149	6	32	89	57

Jersey 1 - 3hr	Motile	PROG	VAP	VSL	VCL	ALH	BCF	STR	LIN
Control	43	5	41	33	74	6	15	56	46
B12 - 0.25 mg/ml	53	34	58	51	93	4	23	87	55
AKG - 0.35 mg/ml	60	44	82	67	136	5	27	83	50
COMBO	51	36	79	63	129	5	25	80	50

Jersey 1 - 6hr	Motile	PROG	VAP	VSL	VCL	ALH	BCF	STR	LIN
Control	2	1	48	38	58	3	8	75	64
B12 - 0.25 mg/ml	37	2	38	28	61	4	15	73	48
AKG - 0.35 mg/ml	36	18	50	42	90	4	22	82	46
COMBO	35	6	45	34	81	5	17	76	43

Jersey 2 - 3hr	Motile	PROG	VAP	VSL	VCL	ALH	BCF	STR	LIN
Control	18	1	35	22	57	5	13	61	38
B12 - 0.25 mg/ml	66	30	51	43	93	5	18	84	47
AKG - 0.35 mg/ml	64	50	78	62	117	5	19	82	56
COMBO	50	38	72	57	124	5	24	80	48

Jersey 2 - 6hr	Motile	PROG	VAP	VSL	VCL	ALH	BCF	STR	LIN
Control	1	0	16	16	35	0	0	50	23
B12 - 0.25 mg/ml	24	1	36	24	51	1	17	65	47
AKG - 0.35 mg/ml	44	5	42	36	68	2	17	86	54
COMBO	46	18	61	46	111	5	21	77	44

Jersey 3 - 0hr									
Control	80	60	100	80	186	8	26	81	46
B12 - 0.25 mg/ml	83	70	89	76	160	7	27	85	51
AKG - 0.35 mg/ml	86	73	95	82	170	7	27	85	50
COMBO	89	74	99	81	177	7	28	84	49

Jersey 3 - 3hr	Motile	PROG	VAP	VSL	VCL	ALH	BCF	STR	LIN
Control	64	22	47	38	88	6	16	81	45
B12 - 0.25 mg/ml	73	52	64	52	104	10	20	81	51

AKG - 0.35 mg/ml	80	44	69	53	118	6	19	79	47
COMBO	77	30	56	44	107	7	19	79	42

Jersey 3 - 6hr	Motile	PROG	VAP	VSL	VCL	ALH	BCF	STR	LIN
Control	16	0.5	38	24	54	1	17	64	47
B12 - 0.25 mg/ml	44	1	37	24	56	3	14	66	44
AKG - 0.35 mg/ml	79	11	46	33	84	6	15	74	41
COMBO	72	12	49	34	98	8	16	71	35

Example 17

In an additional experiment, motility and progressive motility of female and male sex-sorted Deer sperm were checked at 0, 1 and 3 hours after thawing the sex sorted semen samples that were treated with the antioxidant, vitamin B12 at two concentrations: 0.25 mg/ml and 0.35 mg/ml; all samples were treated during staining, catch and prior to cryopreservation (3 step). The OSR was not added to the control sample. The semen samples were derived from two white tailed bucks. Each sample was sorted for both male and female enriched populations of sperm.

TABLE 17: Deer (male and female) – Vitamin B12 (3 step)

0 HR	FEMALE	TOTAL	MOTILE	PROG	VAP	VSL	VCL	ALH	BCF	STR
Buck A	CONTROL	1887	74	53	85	67	157	7	24	78
	0.25	2803	82	53	83	62	157	7	24	74
	0.35	2484	84	55	92	68	169	7	24	74
	MALE									
	CONTROL	2939	81	55	94	70	178	7	24	76
	0.25	3036	76	49	91	66	173	7	24	73
	0.35	2448	86	54	98	71	181	8	24	73
Buck B	FEMALE									
	CONTROL	2025	80	36	92	56	185	8	22	64
	0.25	1531	82	40	91	56	179	7	22	65
	0.35	1859	89	43	105	69	198	8	23	66
	MALE									
	CONTROL	2114	85	39	103	62	202	8	22	63
	0.25	1169	81	35	109	63	219	8	23	61
	0.35	1658	89	46	103	67	197	8	23	66

1 HR	FEMALE	TOTAL	MOTILE	PROG	VAP	VSL	VCL	ALH	BCF	STR
Buck A	CONTROL	1286	64	29	86	57	170	8	21	68
	0.25	1380	78	41	97	64	185	8	21	67
	0.35	1808	80	31	109	68	216	9	22	63

	MALE		MOTILE	PROG	VAP	VSL	VCL	ALH	BCF	STR
	CONTROL	1612	67	27	71	50	141	7	22	73
	0.25	1817	57	23	64	45	125	7	22	70
	0.35	3169	85	52	105	75	198	8	23	72
Buck B	FEMALE		MOTILE	PROG	VAP	VSL	VCL	ALH	BCF	STR
	CONTROL	1371	81	26	65	43	127	6	19	68
	0.25	1541	83	28	84	51	158	8	19	64
	0.35	2637	92	32	116	66	214	9	20	58
	MALE									
	CONTROL	1520	84	48	86	57	169	6	23	70
	0.25	1086	84	46	104	66	203	8	22	67
	0.35	1881	92	46	112	71	216	8	22	65

2 HR	FEMALE	TOTAL	MOTILE	PROG	VAP	VSL	VCL	ALH	BCF	STR
Buck A	CONTROL	1188	58	16	58	42	114	7	18	74
	0.25	1045	75	40	97	65	190	9	20	68
	0.35	877	54	19	68	50	137	8	20	75
	MALE									
	CONTROL	1325	59	13	51	38	101	6	19	77
	0.25	1523	56	24	66	46	130	6	22	70
	0.35	1797	58	39	101	75	193	8	23	76
Buck B	FEMALE		MOTILE	PROG	VAP	VSL	VCL	ALH	BCF	STR
	CONTROL	1125	73	15	56	38	111	7	18	69
	0.25	834	64	11	53	36	106	7	16	68
	0.35	1378	85	26	100	57	190	8	19	60
	MALE									
	CONTROL	1603	77	37	66	46	126	6	19	73
	0.25	866	78	47	95	67	177	7	21	71
	0.35	1760	89	41	78	51	149	7	20	70

As can be easily understood from the foregoing, the basic concepts of the present invention may be embodied in a variety of ways. As such, the particular embodiments, elements, terms, or expressions disclosed by the description, or shown in the figures accompanying this application are not intended to be limiting, but rather are examples of the numerous and varied embodiments generically encompassed by the invention or its equivalents with respect to any particular element thereof. In addition, the specific description of a single embodiment or

element of the invention may not explicitly describe all embodiments or elements possible; many alternatives are implicitly disclosed by the description and figures.

It should be understood that each element of an apparatus or each step of a method may be described by an apparatus term or method term. Such terms can be substituted where desired to make explicit the implicitly broad coverage to which this invention is entitled. As example, it should be understood that all steps of a method may be disclosed as an action, a means for taking that action, or as an element which causes that action. Similarly, each element of an apparatus may be disclosed as the physical element or the action which that physical element facilitates. As another example, the disclosure of a "sorter" should be understood to encompass disclosure of the act of "sorting," whether explicitly discussed or not, and conversely, effective disclosure of the act of "sorting" should be understood to encompass disclosure of a "sorter." Such alternative terms for each element or step are to be understood to be explicitly included in the description.

In addition, it should be understood that unless utilization of a specific term in this application is inconsistent with common use and interpretation of that term, dictionary definitions should be understood to be included in the description for each term as contained in the Random House Webster's Unabridged Dictionary, second edition, each definition hereby incorporated by reference.

Moreover, for the purposes of the present invention, the term "a" or "an" before an item also refers to one or more of that item; for example, "a container" refers to one or more of the containers. As such, the terms "a" or "an", "one or more" and "at least one" can be used interchangeably herein. Further, as used herein the term "or" means "and/or" unless specifically indicated otherwise.

The background section of this patent application provides a statement of the field of endeavor to which the invention pertains. This section may also incorporate or contain paraphrasing of certain United States patents, patent applications, publications, or subject matter of the claimed invention useful in relating information, problems, or concerns about the state of technology to which the invention is drawn toward. It is not intended that any United States patent, patent application, publication, statement or other information cited or incorporated herein be interpreted, construed or deemed to be admitted as prior art with respect to the present invention, and the terms used in those earlier documents which may be similarly used in this

disclosure, shall not alter the intended definition of those same terms as defined or intended herein.

The claims set forth in this specification, if any, are hereby incorporated by reference as part of the description of the current invention, and the applicant expressly reserves the right to use all or a portion of such incorporated content as additional description to support any or all of the claims or any element or component thereof. The applicant further expressly reserves the right to move any portion or all of the incorporated content of such claims or any element or component thereof from the description into the claims, or vice versa, as necessary to define the invention for which protection is sought by this application or by any subsequent application or continuation, division, or continuation-in-part application thereof, or to obtain any benefit for reduction in fees in compliance with relevant patent laws, rules, or regulations of any country or treaty, and such incorporate content shall survive the entire pendency of this application as well as any subsequent continuation, division, continuation-in-part application filings or any reissue or extension thereof.

The claims set forth in this specification are intended to describe the metes and bounds of a limited number of the preferred embodiments of the invention and are not to be construed as the broadest embodiment of the invention or a complete listing of embodiments of the invention that may be claimed. The applicant does not waive any right to develop further claims based upon the description set forth above as a part of any continuation, division, or continuation-in-part, or similar application.

Claims:

1. A method of treating sperm cells during processing to improve cell integrity comprising the steps of:
 - a. providing a sperm cell sample;
 - b. processing the sperm cell sample; and
 - c. adding one or more OSRs in the concentration range of 0.01 mg/ml to 5 mg/ml to the sperm cell sample to form a sperm cell composition.
2. The method as claimed in claim 1, further comprising the step of holding the sperm cell composition at a holding temperature without freezing for a period of time in the range of about 2 seconds to about a week following addition of the one or more OSRs.
3. The method as claimed in claim 2, wherein the holding period is selected from a range selected from the group of: about 2 sec to about 3 min; about 3 min to about 15 min; about 15 min to about 1 hr; about 1 hr to about 8 hrs; about 8 hrs to about 12 hrs; about 12 hrs to about 18 hrs; about 8 hrs to about 24 hrs; about 24 hrs to about 48 hrs; about 48 hrs to about 72 hrs; about 72 hrs to about 96 hrs; about 96 hrs to about 120 hrs; about 120 hrs to about 144 hrs; and about 144 hrs to about 168 hrs.
4. The method of claim 2, wherein the holding temperature is in the range of 4°C and 39°C.
5. The method of claim 4, wherein the holding temperature is in the range of about 4°C to 16°C.
6. A method of transporting processed sperm cells comprising the steps of:
 - a. forming a sperm cell composition according to any one of claims 1-5; and
 - b. transporting the sperm cell composition to a second location.
7. The method as claimed in claim 1, wherein processing the sperm cell sample comprises two or more processing steps selected from the group of: collecting a semen sample; holding; transporting; buffering; chilling; warming; staining; diluting; concentrating; exciting with a laser; electronic charging; deflecting; ablating; sorting; collecting; shaking; oscillating; magnetically separating; oxygenating; labeling; precipitating; centrifuging; resuspending; mixing; dialyzing; cryostabilizing; freezing; thawing; vitrifying; culturing; inseminating; microinjecting; microfluidic processing; microchip processing; jet and air processing; flow cytometry processing; and similar handling techniques.
8. The method as claimed in claim 1, wherein processing comprises a multistep sperm sorting procedure resulting in the collection of one or more enriched sperm cell subpopulations.

9. The method as claimed in claim 8, wherein the sorting procedure includes the step of staining the sperm with a DNA selective dye.
10. The method as claimed in claim 8, wherein the subpopulations comprise at least one gender enriched subpopulation of sperm cells.
11. The method as claimed in claim 8, wherein the sorting procedure includes at least one processing step at a temperature selected from the group consisting of: 5°C to 15°C; 15°C to 20°C; 20°C to 25°C; 25°C to 30°C; 30°C to 35°C; 35°C to 40°C and 40°C to 45°C.
12. The method as claimed in claim 8, wherein the sorting procedure comprises the step of adding an extender to the sperm cell sample or the sperm cell composition, wherein the pH of the extender is in the range of pH 5.5 to pH 7.8.
13. The method as claimed in claim 12, wherein the pH is selected from the group of: about 5.5; about 5.6; about 5.7; about 5.8; about 5.9; about 6.0; about 6.1; about 6.2; about 6.3; about 6.4; about 6.5; about 6.6; about 6.7; about 6.8; about 6.9; about 7.0; about 7.1; about 7.2; about 7.3; about 7.4; about 7.5; about 7.6; about 7.7; and about 7.8.
14. The method as claimed in any one of claims 1-13, wherein the sperm cell sample has been frozen and thawed prior to being further processed.
15. The method as claimed in any one of claims 1-14, wherein the method further comprises the step of freezing the sperm cell composition to form a frozen sperm cell composition.
16. The method as claimed in claim 15, wherein the method further comprises the step of thawing the frozen sperm cell composition.
17. A method of producing an embryo, comprising: forming a sperm cell composition as claimed in claim 1, and using the sperm cell composition for assisted reproductive techniques.
18. The method of producing an embryo according to the method of claim 17, wherein the assisted reproductive technique (ART) is selected from the group consisting of: in vitro fertilization (IVF), artificial insemination (AI), intracytoplasmic sperm injection (ICSI), multiple ovulation and embryo transfer (MOET), and other embryo transfer techniques.
19. The method of producing an embryo according to the method of claim 17, wherein the assisted reproductive technique is in vitro fertilization (IVF) or multiple ovulation and embryo transfer (MOET).
20. The method as claimed in any one of claims 1-19, wherein the OSRs are selected from the group comprising: catalase, SOD, an SOD mimic, glutathione, glutathione reductase, glutathione

peroxidase, pyruvate, mercaptoethanol, BHT, lipoic acid, flavins, quinines, vitamin K (and related vitamers), vitamin B12, vitamin B12 vitamers, vitamin E (and related vitamers), tocopherols, tocotrienols, α -tocopheryl, alpha ketoglutarate (AKG), malondialdehyde (MDA), asymmetric dimethylarginine (ADMA) and biologically active derivatives thereof.

21. The method as claimed in claim 20, wherein the OSRs are selected from the group comprising: vitamin B12, vitamin B12 vitamers, vitamin E, vitamin E vitamers, tocopherols, tocotrienols, α -tocopheryl, alpha ketoglutarate, and derivatives thereof.

22. The method as claimed in claim 20, wherein the one or more OSRs are added to the sperm cell composition at any given step whereby the added OSR is added to be in the range of 0.01 to 5.0 mg/ml in the sperm cell composition.

23. The method as claimed in claim 21, wherein the concentration of the added OSR is selected from the group of: 0.01 to 5.0 mg/ml; 0.01 to 0.25 mg/ml; 0.01 to 0.5 mg/ml; 0.01 to 1 mg/ml; 0.01 to 2.5 mg/ml; 0.01 to 5 mg/ml; 0.05 to 0.1 mg/ml; 0.05 to 1.0 mg/ml; 0.05 to 2.5 mg/ml; 0.1 to 0.25 mg/ml; 0.1 to 0.5 mg/ml; 0.1 to 1 mg/ml; 0.1 to 2.5 mg/ml; 0.1 to 5 mg/ml; 0.15 to 0.45 mg/ml; 0.15 to 0.5 mg/ml; 0.25 to 0.35 mg/ml; 0.25 to 0.5 mg/ml; 0.25 to 1 mg/ml; 0.25 to 2.5 mg/ml; 0.25 to 5 mg/ml; 0.35 to 0.5 mg/ml; 0.35 to 1 mg/ml; 0.35 to 2.5 mg/ml; 0.35 to 5 mg/ml; 0.5 to 1 mg/ml; 0.5 to 2.5 mg/ml; 0.5 to 5 mg/ml; 1 to 2.5 mg/ml; and 1 to 5 mg/ml.

24. The method as claimed in claim 23, wherein the concentration of the added OSR is selected from the group of: about 0.05 mg/ml; about 0.1 mg/ml; about 0.15 mg/ml; about 0.25 mg/ml; about 0.35 mg/ml; about 0.45 mg/ml; and about 0.5 mg/ml.

25. The method as claimed in claim 24, wherein the concentration of the added OSR is about 0.15 mg/ml, about 0.25 mg/ml or about 0.35 mg/ml.

26. The method as claimed in any one of claims 1-25, wherein processing constitutes two or more processing steps and wherein the OSR is added at one or more of the processing steps.

27. A stress reducing media comprising at least one OSR at the appropriate stock concentration to be present in the range of 0.01 mg/ml to 5 mg/ml in the sperm cell composition at the time of processing.

28. The stress reducing media as claimed in claim 27, for sorting sperm cells comprising one or more of the following buffers selected from the group of: Tris, TES, HEPES, TALP, TCA, PBS, citrate, milk and derivatives thereof.

29. The sperm sorting stress reducing media as claimed in claim 27 or 28, wherein the OSR is selected from the group comprising: catalase, SOD, an SOD mimic, glutathione, glutathione reductase, glutathione peroxidase, pyruvate, mercaptoethanol, BHT, lipoic acid, flavins, quinines, vitamin K (and related vitamers), vitamin B12, vitamin B12 vitamers, vitamin E (and related vitamers), tocopherols, tocotrienols, α -tocopheryl, alpha ketoglutarate (AKG), malondialdehyde (MDA), asymmetric dimethylarginine (ADMA) and biologically active derivatives thereof.

30. The sperm sorting stress reducing media as claimed in claim 29, wherein the OSR is selected from the group comprising: vitamin B12, vitamin B12 vitamers, vitamin E, vitamin E vitamers, tocopherols, tocotrienols, α -tocopheryl, alpha ketoglutarate, and derivatives thereof.

31. A method of sorting a sperm cell sample to form one or more subpopulations comprising the steps of:

- a. providing a sperm cell sample;
- b. sorting the sperm cell sample to form one or more subpopulations; and
- c. adding at least one OSR to the sperm cell sample, during one or more of the processing steps, the concentration of the OSR added to the sperm cell sample being in the range of 0.01 mg/ml to 5 mg/ml.

32. The method as claimed in claim 31, wherein the method further comprises the step of staining the sperm cell sample with a DNA selective dye to form a stained sperm cell sample.

33. The method as claimed in claim 31 or 32, wherein the one or more subpopulations comprises at least one gender enriched population of X-chromosome bearing or Y-chromosome bearing sperm cells having a DNA selective dye associated with their DNA.

34. The method as claimed in claim 31, wherein the OSR is selected from the group comprising: catalase, SOD, an SOD mimic, glutathione, glutathione reductase, glutathione peroxidase, pyruvate, mercaptoethanol, BHT, lipoic acid, flavins, quinines, vitamin K (and related vitamers), vitamin B12, vitamin B12 vitamers, vitamin E (and related vitamers), tocopherols, tocotrienols, α -tocopheryl, alpha ketoglutarate (AKG), malondialdehyde (MDA), asymmetric dimethylarginine (ADMA) and biologically active derivatives thereof.

35. The method as claimed in claim 34, wherein the OSR is selected from the group comprising: vitamin B12, vitamin B12 vitamers, vitamin E, vitamin E vitamers, tocopherols, tocotrienols, α -tocopheryl, alpha ketoglutarate, and derivatives thereof.

36. The method as claimed in any one of claims 31-35, wherein the method further comprises the step of freezing the one or more subpopulations.
37. The method as claimed in claim 36, wherein the method further comprises the step of thawing the frozen gender enriched population of X-chromosome bearing or Y-chromosome bearing sperm cells and using it for ART.
38. The method as claimed in claim 31, wherein the method further comprises the step of allowing a time period to elapse after the addition of the antioxidant, the time period being in the range of about 3 seconds to about 72 hours.
39. The method as claimed in claim 38, wherein the time period is selected from the group consisting of about 3 seconds to about 3 hours; about 3 hours to about 6 hours; about 6 hours to about 12 hours; about 12 hours to about 18 hours; about 18 hours to about 24 hours; about 24 hours to about 36 hours; about 36 hours to about 48 hours; about 48 hours to about 60 hours; and about 60 hours to about 72 hours.
40. The method of claim 39, wherein the concentration of the added OSR is in the range of 0.05 to 0.5 mg/ml in the sperm cell sample.
41. The method as claimed in claim 31, wherein the concentration of the added OSR is selected from the group of: about 0.05 mg/ml; about 0.1 mg/ml; about 0.15 mg/ml; about 0.25 mg/ml; about 0.35 mg/ml; about 0.45 mg/ml; and about 0.5 mg/ml.
42. The method as claimed in claim 31, wherein the method further comprises the step of adding a buffer, a media and/or an extender to the sperm cell sample wherein the buffer, media and/or extender is in a pH range of 6.5 to 7.5.
43. The method as claimed in claim 42, wherein the pH is selected from the group consisting of about 6.5; about 6.6; about 6.7; about 6.8; about 6.9; about 7.0; about 7.1; about 7.2; about 7.3; about 7.4; and about 7.5.
44. The method as claimed in claim 31, wherein at least one of the processing steps is carried out within a temperature range selected from the group consisting of about 5°C to about 15°C; about 15°C to about 20°C; about 20°C to about 25°C; about 25°C to about 30°C; about 30°C to about 35°C; about 35°C to about 40°C and about 40°C to about 45°C.
45. The method as claimed in any one of claims 31-44, wherein the sperm cell sample is a frozen thawed sperm cell sample.

46. A method of sorting a sperm cell sample comprising the steps of:
- a. providing a sperm cell sample;
 - b. staining the sperm cell sample with a first media;
 - c. sorting the sperm cell sample to form at least one subpopulation contained in a second media; and
 - d. freezing the at least one subpopulation in a third media;
- wherein at least one of the first media, the second media or the third media contains at least one OSR at a final processing concentration in the range of 0.01 mg/ml to 5 mg/ml.
47. The method of claim 46, wherein the OSR is selected from the group comprising: catalase, SOD, an SOD mimic, glutathione, glutathione reductase, glutathione peroxidase, pyruvate, mercaptoethanol, BHT, lipoic acid, flavins, quinines, vitamin K (and related vitamers), vitamin B12, vitamin B12 vitamers, vitamin E (and related vitamers), tocopherols, tocotrienols, α -tocopheryl, alpha ketoglutarate (AKG), malondialdehyde (MDA), asymmetric dimethylarginine (ADMA) and biologically active derivatives thereof.
48. The method as claimed in claim 47, wherein the OSR is selected from the group comprising: vitamin B12, vitamin B12 vitamers, vitamin E, vitamin E vitamers, tocopherols, tocotrienols, α -tocopheryl, alpha ketoglutarate, and derivatives thereof.
49. The method of claim 47, wherein the concentration of the added OSR is in the range of 0.05 to 0.5 mg/ml in the sperm cell sample.
50. The method of claim 49, wherein the concentration of the added OSR is selected from the group of: about 0.05 mg/ml; about 0.1 mg/ml; about 0.15 mg/ml; about 0.25 mg/ml; about 0.35 mg/ml; about 0.45 mg/ml; and about 0.5 mg/ml.
51. The method of any one of claims 46-50, wherein the at least one OSR is added to: the first media, or the second media, or the third media.
52. The method of any one of claims 46-50, wherein the at least one OSR is added to: the first media and the second media, or the first and third media, or the second and third media.
53. The method of any one of claims 46-50, wherein the at least one OSR is added to: the first media, and the second media, and the third media.

54. The method of any one of claims 1-26 or 31-53, wherein the sperm cell sample is derived from a human, bovine, swine, ovine, equine, deer, elk, buffalo, canine, feline, chimpanzee, gorilla, whale, dolphin and other marine mammals.

55. A method of sorting a sperm cell sample comprising the steps of:

- a. providing a sperm cell sample;
- b. staining the sperm cell sample with a first media; and
- c. sorting the sperm cell sample to form at least one subpopulation contained in a second media;

wherein at least one of the first media or the second media contains at least one OSR at a final processing concentration in the range of 0.01 mg/ml to 5 mg/ml.

56. The method of claim 55, wherein the OSR is selected from the group comprising: catalase, SOD, an SOD mimic, glutathione, glutathione reductase, glutathione peroxidase, pyruvate, mercaptoethanol, BHT, lipoic acid, flavins, quinines, vitamin K (and related vitamers), vitamin B12, vitamin B12 vitamers, vitamin E (and related vitamers), tocopherols, tocotrienols, α -tocopheryl, alpha ketoglutarate (AKG), malondialdehyde (MDA), asymmetric dimethylarginine (ADMA) and biologically active derivatives thereof.

57. The method as claimed in claim 56, wherein the OSR is selected from the group comprising: vitamin B12, vitamin B12 vitamers, vitamin E, vitamin E vitamers, tocopherols, tocotrienols, α -tocopheryl, alpha ketoglutarate, and derivatives thereof.

58. The method of claim 56, wherein the concentration of the added OSR is in the range of 0.05 to 0.5 mg/ml in the sperm cell sample.

59. The method of claim 56, wherein the concentration of the added OSR is selected from the group of: about 0.05 mg/ml; about 0.1 mg/ml; about 0.15 mg/ml; about 0.25 mg/ml; about 0.35 mg/ml; about 0.45 mg/ml; and about 0.5 mg/ml.

60. The method of any one of claims 55-59, wherein the at least one OSR is added to the first media or the second media.

61. The method of any one of claims 55-59, wherein the at least one OSR is added to both the first media and the second media.

62. The method of any one of claims 55-61, wherein the sperm cell sample is derived from a human, bovine, swine, ovine, equine, deer, elk, buffalo, canine, feline, chimpanzee, gorilla, whale, dolphin and other marine mammals.

63. A processed sperm sample comprising a sperm cell sample that has been subjected to one or more processing steps and contains one or more OSRs in the range of 0.01 mg/ml to 5 mg/ml.
64. The processed sperm sample as claimed in claim 63, wherein the OSR is selected from the group comprising: catalase, SOD, an SOD mimic, glutathione, glutathione reductase, glutathione peroxidase, pyruvate, mercaptoethanol, BHT, lipoic acid, flavins, quinines, vitamin K (and related vitamers), vitamin B12, vitamin B12 vitamers, vitamin E (and related vitamers), tocopherols, tocotrienols, α -tocopheryl, alpha ketoglutarate (AKG), malondialdehyde (MDA), asymmetric dimethylarginine (ADMA) and biologically active derivatives thereof.
65. The processed sperm sample as claimed in claim 64, wherein the OSR is selected from the group comprising: vitamin B12, vitamin B12 vitamers, vitamin E, vitamin E vitamers, tocopherols, tocotrienols, α -tocopheryl, alpha ketoglutarate, and derivatives thereof.
66. The processed sperm sample of any one of claims 63-65, wherein the sperm cell sample has been sorted.
67. The processed sperm sample of claim 66, wherein the sperm cell sample has been gender sorted.
68. The processed sperm sample of any one of claims 63-67, wherein the sperm cell sample is unfrozen.
69. The processed sperm sample of any one of claims 63-67, wherein the sperm cell sample is frozen.
70. The processed sperm sample of any one of claims 63-69, wherein the sperm cell sample is derived from a human, bovine, swine, ovine, equine, deer, elk, buffalo, canine, feline, chimpanzee, gorilla, whale, dolphin and other marine mammals.
71. A method of fertilizing one or more eggs, comprising the steps of:
- a. providing a sperm cell sample in a media making a sperm cell composition, wherein the media contains one or more OSRs having a concentration appropriate for making a sperm cell composition having an OSR concentration in the range of 0.01 mg/ml to 5 mg/ml; and
 - b. mixing the one or more eggs with the sperm cell sample to form a sperm cell composition.
72. The method of claim 71, wherein the OSR is selected from the group comprising: catalase, SOD, an SOD mimic, glutathione, glutathione reductase, glutathione peroxidase, pyruvate,

mercaptoethanol, BHT, lipoic acid, flavins, quinines, vitamin K (and related vitamers), vitamin B12, vitamin B12 vitamers, vitamin E (and related vitamers), tocopherols, tocotrienols, α -tocopheryl, alpha ketoglutarate (AKG), malondialdehyde (MDA), asymmetric dimethylarginine (ADMA) and biologically active derivatives thereof.

73. The method as claimed in claim 72, wherein the OSR is selected from the group comprising: vitamin B12, vitamin B12 vitamers, vitamin E, vitamin E vitamers, tocopherols, tocotrienols, α -tocopheryl, alpha ketoglutarate, and derivatives thereof.

74. The method of claim 72, wherein the concentration of the added OSR is in the range of 0.05 to 0.5 mg/ml in the sperm cell composition.

75. The method of claim 72, wherein the concentration of the added OSR is selected from the group of: about 0.05 mg/ml; about 0.1 mg/ml; about 0.15 mg/ml; about 0.25 mg/ml; about 0.35 mg/ml; about 0.45 mg/ml; and about 0.5 mg/ml.

76. The method of any one of claims 71-75, wherein the sperm cell composition has been sorted.

77. The method of claim 76, wherein the sperm cell composition has been gender sorted.

78. The method of any one of claims 1-13, 15-26, 31-44, 46-54, or 71-77, wherein the sperm cell sample is unfrozen.

79. The method of any one of claims 15-26, 46-54, 55-62, or 71-77, wherein the sperm cell sample is frozen.

80. The method of any one of claims 71-77, wherein the sperm cell sample is derived from a human, bovine, swine, ovine, equine, deer, elk, buffalo, canine, feline, chimpanzee, gorilla, whale, dolphin and other marine mammals.

81. An embryo produced by the method comprising the steps of:

- a. providing a sperm cell sample in a media, wherein the media contains at least one OSR having a concentration in the range of 0.01 mg/ml to 5 mg/ml; and
- b. mixing the one or more eggs with the sperm cell sample to produce an embryo.

82. The embryo as claimed in claim 81, wherein the OSR is selected from the group comprising: catalase, SOD, an SOD mimic, glutathione, glutathione reductase, glutathione peroxidase, pyruvate, mercaptoethanol, BHT, lipoic acid, flavins, quinines, vitamin K (and related vitamers), vitamin B12, vitamin B12 vitamers, vitamin E (and related vitamers),

tocopherols, tocotrienols, α -tocopheryl, alpha ketoglutarate (AKG), malondialdehyde (MDA), asymmetric dimethylarginine (ADMA) and biologically active derivatives thereof.

83. The embryo as claimed in claim 82, wherein the OSR is selected from the group comprising: vitamin B12, vitamin B12 vitamers, vitamin E, vitamin E vitamers, tocopherols, tocotrienols, α -tocopheryl, alpha ketoglutarate, and derivatives thereof.

84. The embryo of claim 81, wherein the concentration of the added OSR is in the range of 0.05 to 0.5 mg/ml in the sperm cell sample.

85. The embryo of claim 81, wherein the concentration of the added OSR is selected from the group of: about 0.05 mg/ml; about 0.1 mg/ml; about 0.15 mg/ml; about 0.25 mg/ml; about 0.35 mg/ml; about 0.45 mg/ml; and about 0.5 mg/ml.

86. The embryo of any one of claims 81-85, wherein the sperm cell sample has been sorted.

87. The embryo of claim 86, wherein the sperm cell sample has been gender sorted.

88. The embryo of any one of claims 81-87, wherein the sperm cell sample is unfrozen.

89. The embryo of any one of claims 81-87, wherein the sperm cell sample is frozen.

90. The embryo of any one of claims 81-89, wherein the sperm cell sample is derived from a human, bovine, swine, ovine, equine, deer, elk, buffalo, canine, feline, chimpanzee, gorilla, whale, dolphin and other marine mammals.

91. A method of fertilizing one or more eggs comprising the steps of:

- a. providing a sperm cell sample;
- b. adding a first media;
- c. staining the sperm cell sample in the first media;
- d. sorting the sperm cell sample to form one or more subpopulations of sperm cells;
- e. collecting the subpopulation of sperm cells in a second media;
- f. mixing the subpopulation of sperm cells with one or more eggs to fertilize one or more of the eggs;

wherein the first media and/or the second media contains at least one OSR in the range of 0.01 mg/ml to 5 mg/ml, and wherein the OSR containing media may be prepared before addition to the sperm cell sample or by addition of an OSR stock solution to the sperm cell sample solution.

92. A method of fertilizing one or more eggs comprising the steps of:

- a. providing a sperm cell sample;
- b. adding a first media;

- c. staining the sperm cell sample in the first media;
- d. sorting the sperm cell sample to form one or more subpopulations of sperm cells;
- e. collecting the subpopulation of sperm cells in a second media;
- f. freezing the subpopulation of sperm cells in a third media;
- g. thawing the subpopulation of sperm cells; and
- h. mixing the thawed subpopulation of sperm cells with one or more eggs to fertilize one or more of the eggs;

wherein at least one of the first media, the second media or the third media contains at least one OSR having a concentration in the range of 0.01 mg/ml to 5 mg/ml, and wherein the OSR containing media may be prepared before addition to the sperm cell sample or by addition of an OSR stock solution to the sperm cell sample solution.

93. The method as claimed in claim 91 or 92, wherein the OSR is selected from the group comprising: catalase, SOD, an SOD mimic, glutathione, glutathione reductase, glutathione peroxidase, pyruvate, mercaptoethanol, BHT, lipoic acid, flavins, quinines, vitamin K (and related vitamers), vitamin B12, vitamin B12 vitamers, vitamin E (and related vitamers), tocopherols, tocotrienols, α -tocopheryl, alpha ketoglutarate (AKG), malondialdehyde (MDA), asymmetric dimethylarginine (ADMA) and biologically active derivatives thereof.

94. The method as claimed in claim 93, wherein the OSR is selected from the group comprising: vitamin B12, vitamin B12 vitamers, vitamin E, vitamin E vitamers, tocopherols, tocotrienols, α -tocoperyl, alpha ketoglutarate, and derivatives thereof.

95. The method of claim 93, wherein the concentration of the added OSR is in the range of 0.05 to 0.5 mg/ml in the sperm cell composition.

96. The method of claim 93, wherein the concentration of the added OSR is selected from the group of: about 0.05 mg/ml; about 0.1 mg/ml; about 0.15 mg/ml; about 0.25 mg/ml; about 0.35 mg/ml; about 0.45 mg/ml; and about 0.5 mg/ml.

97. The method of any one of claims 91-96, wherein the sperm cell sample is unfrozen.

98. The method of any one of claims 91-96, wherein the sperm cell sample is frozen.

99. The method of any one of claims 91-98, wherein the sperm cell sample is derived from a human, bovine, swine, ovine, equine, deer, elk, buffalo, canine, feline, chimpanzee, gorilla, whale, dolphin and other marine mammals.

100. The method of any one of claims 71-80 or 91-99, wherein the eggs were cultured in maturation media.

101. The method of claim 100, wherein the maturation media comprises FBS, pyruvate, chorionic gonadotropin, FSH, estradiol and at least one antibiotic.

102. The method of claim 101, wherein the maturation media also comprises TCM-199.

103. The method of claim 102, wherein the egg was cultured in maturation media comprising TCM-199, FBS, pyruvate, chorionic gonadotropin, FSH, estradiol and at least one antibiotic in the approximate ratio of 9:1:0.02:0.1:0.01:0.01:0.02 by volume, respectively.

104. A sorted embryo produced by the method comprising:

- a. providing a sperm cell sample;
- b. adding a first media;
- c. staining the sperm cell sample in the first media;
- d. sorting the sperm cell sample to form one or more subpopulations of sperm cells;
- e. collecting the subpopulation of sperm cells in a second media; and
- f. mixing the subpopulation of sperm cells with one or more eggs to produce one or more embryos;

wherein the first media and/or the second media contains at least one OSR in the range of 0.01 mg/ml to 5 mg/ml, and wherein the OSR containing media may be prepared before addition to the sperm cell sample or by addition of an OSR stock solution to the sperm cell sample solution.

105. A sorted embryo produced by the method comprising the steps of:

- a. providing a sperm cell sample;
- b. adding a first media;
- c. staining the sperm cell sample with a first media;
- d. sorting the sperm cell sample to form at least one subpopulation of sperm cells;
- e. collecting the subpopulation of sperm cells in a second media;
- f. freezing the subpopulation in a third media;
- g. thawing the subpopulation; and
- h. mixing the subpopulation of sperm cells with one or more eggs to produce one or more embryos,

wherein at least one of the first media, the second media or the third media contains at least one OSR having a concentration in the range of 0.01 mg/ml to 5 mg/ml, and wherein the OSR

containing media may be prepared before addition to the sperm cell sample or by addition of an OSR stock solution to the sperm cell sample solution.

106. The embryo as claimed in claim 104 or 105, wherein the OSR is selected from the group comprising: catalase, SOD, an SOD mimic, glutathione, glutathione reductase, glutathione peroxidase, pyruvate, mercaptoethanol, BHT, lipoic acid, flavins, quinines, vitamin K (and related vitamers), vitamin B12, vitamin B12 vitamers, vitamin E (and related vitamers), tocopherols, tocotrienols, α -tocopheryl, alpha ketoglutarate (AKG), malondialdehyde (MDA), asymmetric dimethylarginine (ADMA) and biologically active derivatives thereof.

107. The embryo as claimed in claim 106, wherein the OSR is selected from the group comprising: vitamin B12, vitamin B12 vitamers, vitamin E, vitamin E vitamers, tocopherols, tocotrienols, α -tocoperyl, alpha ketoglutarate, and derivatives thereof.

108. The embryo of claim 106, wherein the concentration of the added OSR is in the range of 0.05 to 0.5 mg/ml in the sperm cell sample.

109. The embryo of claim 106, wherein the concentration of the added OSR is selected from the group of: about 0.05 mg/ml; about 0.1 mg/ml; about 0.15 mg/ml; about 0.25 mg/ml; about 0.35 mg/ml; about 0.45 mg/ml; and about 0.5 mg/ml.

110. The embryo of any one of claims 104-109, wherein the sperm cell sample is unfrozen.

111. The embryo of any one of claims 104-109, wherein the sperm cell sample is frozen.

112. The embryo of any one of claims 104-111, wherein the sperm cell sample is derived from a human, bovine, swine, ovine, equine, deer, elk, buffalo, canine, feline, chimpanzee, gorilla, whale, dolphin and other marine mammals.

113. The embryo of any one of claims 104-112, wherein the egg was cultured in maturation media.

114. The embryo of claim 113, wherein the maturation media comprises FBS, pyruvate, chorionic gonadotropin, FSH, estradiol and at least one antibiotic.

115. The embryo of claim 114, wherein the maturation media further comprises TCM-199.

116. The embryo of any claim 115, wherein the egg was cultured in maturation media comprising TCM-199, FBS, pyruvate, chorionic gonadotropin, FSH, estradiol and at least one antibiotic in the approximate ratio of 9:1:0.02:0.1:0.01:0.01:0.02 by volume, respectively.

117. A sperm cell composition comprising:
- a. a sperm cell sample; and
 - b. at least one OSR having a concentration in the range of 0.01 mg/ml to 5 mg/ml.
118. The sperm cell composition of claim 117, wherein the sperm cell sample has been sorted.
119. The sperm cell composition of claim 117 or 118, further comprising a stain.
120. The sperm cell composition of any one of claims 117-119, further comprising an extender or media.
121. The sperm cell composition of any one of claims 117-120, further comprising a cryoprotectant.
122. The sperm cell composition of any one of claims 117-121, wherein the OSR is selected from the group comprising: catalase, SOD, an SOD mimic, glutathione, glutathione reductase, glutathione peroxidase, pyruvate, mercaptoethanol, BHT, lipoic acid, flavins, quinines, vitamin K (and related vitamers), vitamin B12, vitamin B12 vitamers, vitamin E (and related vitamers), tocopherols, tocotrienols, α -tocopheryl, alpha ketoglutarate (AKG), malondialdehyde (MDA), asymmetric dimethylarginine (ADMA) and biologically active derivatives thereof.
123. The sperm cell composition of claim 122, wherein the OSR is selected from the group comprising: vitamin B12, vitamin B12 vitamers, vitamin E, vitamin E vitamers, tocopherols, tocotrienols, α -tocoperyl, alpha ketoglutarate, and derivatives thereof.
124. The sperm cell composition of any one of claims 122-123, wherein the concentration of the added OSR is in the range of 0.05 to 0.5 mg/ml in the sperm cell sample.
125. The sperm cell composition of claim 124, wherein the concentration of the added OSR is selected from the group of: about 0.05 mg/ml; about 0.1 mg/ml; about 0.15 mg/ml; about 0.25 mg/ml; about 0.35 mg/ml; about 0.45 mg/ml; and about 0.5 mg/ml.
126. The sperm cell composition of any one of claims 117-125, wherein the sperm cell sample is unfrozen.
127. The sperm cell composition of any one of claims 117-125, wherein the sperm cell sample is frozen.
128. The sperm cell composition of any one of claims 117-127, wherein the sperm cell sample is derived from a human, bovine, swine, ovine, equine, deer, elk, buffalo, canine, feline, chimpanzee, gorilla, whale, dolphin and other marine mammals.

129. A maturation media for ART, comprising FBS, pyruvate, chorionic gonadotropin, FSH, estradiol and at least one antibiotic.
130. The maturation media of claim 129, further comprising TCM-199.
131. The maturation media of claim 130, comprising TCM-199, FSH, chorionic gonadotropin, estradiol, pyruvate and at least one antibiotic in the approximate ratio of 9:1:0.02:0.1:0.01:0.01:0.02 by volume, respectively.
132. The processed sperm sample as claimed in any one of claims 63-70 that is frozen.
133. The embryo as claimed in any one of claims 81-90 or 104-116 that is frozen or vitrified.
134. The sperm cell composition as claimed in any one of claims 117-128 that is frozen.
135. The method as claimed in any one of claims 1-16, 31-62, 71-80, or 91-103, wherein the sperm cell sample has been frozen and thawed prior to further processing, put through a multistep sorting procedure, and used directly in ART without freezing.
136. The method as claimed in any one of claims 1-16, 31-62, 71-80, or 91-103, wherein the sperm cell sample has been frozen and thawed prior to further processing, put through a multistep sorting procedure, and frozen.
137. The method as claimed in any one of claims 1-16, 31-62, 71-80, or 91-103, wherein the sperm cell sample is unfrozen, put through a multistep sorting procedure, and used directly in ART without freezing.
138. The method as claimed in any one of claims 1-16, 31-62, 71-80, or 91-103, wherein the sperm cell sample is unfrozen, put through a multistep sorting procedure, and frozen.
139. The method as claimed in any one of claims 1-16, 31-62, 71-80, or 91-103, wherein one or more OSRs are added in the staining step.
140. The method as claimed in any one of claims 1-16, 31-62, 71-80, or 91-103, wherein one or more OSRs are added in the collection step following sorting.
141. The method as claimed in any one of claims 1-16, 31-62, 71-80, or 91-103, wherein one or more OSRs are added in the cryogenic preparation step prior to freezing.
142. The method as claimed in any one of claims 1-16, 31-62, 71-80, or 91-103, wherein one or more OSRs are added in the staining step and collection step.
143. The method as claimed in any one of claims 1-16, 31-62, 71-80, or 91-103, wherein one or more OSRs are added in the collection step and cryogenic preparation step prior to freezing.

144. The method as claimed in any one of claims 1-16, 31-62, 71-80, or 91-103, wherein one or more OSRs are added in the staining step, the collection step and the cryogenic preparation step prior to freezing.

145. The method as claimed in any one of claims 139-144, wherein at least one OSR is a vitamer of vitamin B12 and added at the concentration of 0.25 mg/ml in the sperm cell suspension.

146. The method as claimed in any one of claims 139-144, wherein at least one OSR is a vitamer of vitamin B12 and added at a concentration in the range of 0.15 mg/ml to 0.5 mg/ml in the sperm cell suspension.

147. The method as claimed in any one of claims 139-144, wherein at least one OSR is a vitamer of vitamin E and added at a concentration in the range of 0.15 mg/ml to 0.5 mg/ml in the sperm cell suspension.

148. The method as claimed in any one of claims 139-144, wherein at least one OSR is an active form of AKG and added at a concentration in the range of 0.15 mg/ml to 0.5 mg/ml in the sperm cell suspension.

149. The method as claimed in any one of claims 139-144, wherein two OSRs are used in combination selected from the group comprising: a vitamer of vitamin B12 added at a concentration in the range of 0.15 mg/ml to 0.5 mg/ml, a vitamer of vitamin E added at a concentration in the range of 0.15 mg/ml to 0.5 mg/ml, and an active derivative of AKG at a concentration in the range of 0.15 mg/ml to 0.5 mg/ml in the sperm cell suspension.

150. The method as claimed in any one of claims 1-16, 31-62, 71-80, or 91-103, wherein the sperm cell sample contains unwanted dead cells.

151. The method as claimed in claim 150, wherein the sperm cell sample is manually ablated to kill unwanted cell types within the sperm cell sample.




FIG. 1

Figure 2








Figure 3







INTERNATIONAL SEARCH REPORT

International application No.

PCT/US12/40553

A. CLASSIFICATION OF SUBJECT MATTER

IPC(8) - A01K 67/02; A01N 01/02; G01N 01/30 (2012.01)

USPC - 435/2, 40.5; 800/24

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC(8): A01K 67/02; A01N 01/02, 01/30 (2012.01)

USPC: 435/2, 40.5; 800/24

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Micropatent (US-G, US-A, EP-A, EP-B, WO, JP-bib, DE-C,B, DE-A, DE-T, DE-U, GB-A, FR-A); Google Patents; Google; organic stress reducing agent, OSR, vitamin, antioxidant, sorting, gender-enriched, (IVF or AI or ICSI or MOET), (catalase or SOD or glutathione), (buffer* or TRIS or TES or HEPES or TALP or TCA or PBS or citrate or milk), stain*, freeze, cryoprotectant, thaw*, media

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X --- Y	US 2009/0176271 A1 (DURACK, G et al.) July 9, 2009, paragraphs [0012], [0014], [0034], [0045], [0046], [0113], [0759], [0760], [0773], [0776], [0777], [0780], [0781], [0783], [0784], [0787], [0792], [0793], [0950], [0951], [1043], [1044], [1099], [1102], [1103], [1106], [1197], [1349]-[1354], [1405], [1422], [2154], [2155], [2164], [2165], [2185], [2186], [2348], [2281], [2282], [2379]	1-5, 6/1, 6/2, 6/3, 6/4, 6/5, 7-13, 17-19, 27, 28, 29/27, 29/28, 31, 32, 33/31, 33/32, 34, 38-44, 46, 47, 49, 50, 51/46, 51/47, 51/49, 51/50, 52/46, 52/47, 52/49, 52/50, 55, 56, 58, 59, 60/55, 60/56, 60/58, 60/59, 61/55, 61/56, 61/58, 61/59, 63, 64, 66/63, 66/64, 67, 71, 72, 74, 75, 76/71, 76/72, 76/74, 76/75, 77/76/71, 77/76/72, 77/76/74, 77/76/75, 81, 82, 84, 85, 86/81, 86/82, 86/84, 86/85, 87/86/81, 87/86/82, 87/86/84, 87/86/85, 91, 92, 93/91, 93/92, 95/93/91, 95/93/92, 96/93/91, 96/93/92, 104, 105, 106/104, 106/105, 108/106/104, 108/106/105, 109, 117, 118, 119/117, 119/118

Further documents are listed in the continuation of Box C.



* Special categories of cited documents:	“T” later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
“A” document defining the general state of the art which is not considered to be of particular relevance	“X” document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
“E” earlier application or patent but published on or after the international filing date	“Y” document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
“L” document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	“&” document member of the same patent family
“O” document referring to an oral disclosure, use, exhibition or other means	
“P” document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search
04 September 2012 (04.09.2012)

Date of mailing of the international search report

02 OCT 2012

Name and mailing address of the ISA/US
Mail Stop PCT, Attn: ISA/US, Commissioner for Patents
P.O. Box 1450, Alexandria, Virginia 22313-1450
Facsimile No. 571-273-3201

Authorized officer:
Shane Thomas

PCT Helpdesk: 571-272-4300
PCT OSP: 571-272-7774

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US12/40553

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 2009/0176271 A1 (DURACK, G et al.) July 9, 2009, paragraphs [0012], [0014], [0034], [0045], [0046], [0113], [0759], [0760], [0773], [0776], [0777], [0780], [0781], [0783], [0784], [0787], [0792], [0793], [0950], [0951], [1043], [1044], [1099], [1102], [1103], [1106], [1197], [1349]-[1354], [1405], [1422], [2154], [2155], [2164], [2165], [2185], [2186], [2348], [2281], [2282], [2379]	30/29/28, 30/29/27, 35, 48, 51/48, 53, 53/48, 57, 60/57, 65, 66/65, 73, 76/73, 77/76/73, 83, 86/83, 87/86/83, 94/93/91, 94/93/92, 107/106/104, 107/106/105
Y	US 6235783 A (SURAI, P. et al.) May 22, 2001, column 9, lines 10-20	30/29/28, 30/29/27, 35, 48, 51/48, 53/48, 57, 60/57, 65, 66/65, 73, 76/73, 77/76/73, 83, 86/83, 87/86/83, 94/93/91, 94/93/92, 107/106/104, 107/106/105
Y	US 2008/0026361 A1 (OSTERMEIER, C et al.) January 31, 2008, paragraphs [0045], [0046]	53
Y	US 2002/0028849 A1 (GODKIN, J et al) March 7, 2002, paragraphs [0034], [0054], [0057]	129-131
Y	US 6258998 B1 (DAMIANI, P et al.) July 10, 2001, column 47, lines 25-30	129-131

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US12/40553

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

- 1. Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

- 2. Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

- 3. Claims Nos.: 14-16, 20-26, 36, 37, 45, 54, 62, 68-70, 78-80, 88-90, 97-103, 110-116, 120-128, 132-151
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

- 1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
- 2. As all searchable claims could be searched without effort justifying additional fees, this Authority did not invite payment of additional fees.
- 3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

- 4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
- The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
- No protest accompanied the payment of additional search fees.